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ABSTRACT
Colorectal cancer (CRC) is the second leading cause of cancer deaths in
the United States. The major cause of death is metastasis and the frequent
target organ is the liver. When diagnosed early at a localized stage, the five year
survival rate after resection is 90%. However, after metastasis has occurred, this
drops to less than 12%. Metastasis is often asymptomatic and diagnosed at the
final stage when therapeutic options are limited. Because of this, the genetic and
cellular mechanisms regulating metastasis are still poorly understood. Recent
studies have shown that prior to the arrival of cancer cells at the secondary
organ, molecular signals from the tumor direct the recruitment of bone marrow
derived cells (BMDCs) to create a pre-metastatic niche where cancer cells can
attach and develop into a metastatic lesion. Identifying and understanding these
signals can lead to the development of methods for early diagnosis or identifying
targets for intervention.
Using an orthotopic mouse model of CRC liver metastasis, we performed
microarray analyses of the liver microenvironment in tumor bearing mice before
and after the arrival of metastatic cells in the liver. We found that Lipocalin-2
(Lcn2) was highly expressed in the liver and sera of mice bearing highly
metastatic cells. Its expression is upregulated in tumors of epithelial origin, but
has contrasting roles in metastasis. In the clinic, elevated LCN2 is associated
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with poor prognosis. The role of LCN2 in the tumor microenvironment has not
thoroughly been studied. Our studies show overexpression of Lcn2 in mouse
colon cancer cells had little impact on tumor growth or invasiveness; however,
invasion assays show that Lcn2 from some stromal cells increases the
invasiveness of colon tumor cells. These studies will allow us to better elucidate
the role of Lcn2 in tumor and stromal cells in the early stages of CRC metastasis
and in anticancer therapy.
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CHAPTER 1
INTRODUCTION
1.1 COLORECTAL CANCER
Colorectal cancer (CRC), which consists of cancers originating in the
colon or rectum, is one of the deadliest cancers both in the United States and in
the world. The tumors are often slow growing, beginning as a benign polyp and
developing into a malignant tumor over multiple years or even decades. Three
types of polyps, adenomatous, hyperplastic, and dysplastic, may all form, but
adenomatous polyps most frequently develop into a harmful adenocarcinoma
(American Cancer Society, 2015).
In the United States, CRC ranks as the fourth most diagnosed cancer and
the second leading cause of cancer related deaths (Howlader et al., 2014).
According to the 2012 GLOBOCAN report by the World Health Organization
(WHO), CRC was diagnosed in 1,361,000 cases and responsible for 694,000
deaths worldwide, accounting for approximately 10% of all cancer cases (WHO).
As the global population continues to live longer due to better healthcare, the
incidence of colorectal cancer will, as a result, also rise significantly.
Colorectal cancer is problematic not only because of its slow early growth,
but also due to a lack of symptoms until the tumor is large enough to be
symptomatic and clinically detectable. When diagnosed early, colorectal tumors
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are usually well contained in the colon and the localized tumors can easily
be surgically resected, contributing to a five year survival rate of 90.1%
(Howlader et al., 2014). However, if the diagnosis occurs after the tumor has
spread to the lymph nodes, the tumor is classified as stage II or III and the fiveyear survival drops to 60% and 40%, respectively. In Stage IV cancer where the
tumors have metastasized to distant organs, surgical resection of disseminated
metastatic lesions is difficult and tumor cell populations have increased
heterogeneity and drug resistance. The average five-year survival for all
colorectal cancer diagnoses is 64.9%, but for patients with metastatic disease,
the survival rate is a mere 13.1% (Howlader et al., 2014). Furthermore, nearly
70% of patients dying from CRC burden have metastasis present as revealed by
autopsy (Hugen et al., 2014; Welch and Donaldson, 1979). Colonoscopies
currently remain as the best screening method for early detection of colorectal
cancer development and the removal of polyps; however, less invasive methods
such as stool DNA testing (e.g. Cologuard) are quickly becoming reliably
accurate and significantly cheaper, providing a viable alternative to a
colonoscopy (American Cancer Society, 2014).The primary reason for mortality
in CRC and many other solid tumors, which includes all non-leukemic and nonlymphoma tumors, is the presence of metastatic disease and understanding the
underlying molecular and cellular mechanisms that drive metastasis may lead to
therapeutic strategies and interventions to improve patients’ clinical outcomes
(Obenauf and Massagué, 2015).
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1.2 METASTASIS
One of the hallmark properties of cancer cells is the ability to activate
invasion and metastasis (Hanahan and Weinberg, 2011). This is the ability of
cancer cells to spread from the primary tumor to lymphatic organs and into
circulation and subsequently grow in distant organs. Treatment of a primary
tumor frequently only requires surgery and/or adjuvant chemotherapy; however,
metastatic tumors that have spread throughout the body are difficult to remove
surgically. They form heterogeneous populations that typically harbor additional
mutations as compared to the primary tumor cells and that confer variable
responses to chemotherapy. Patients with solid tumors that already present with
metastasis upon diagnosis are given a stage IV diagnosis that correlates with
low five-year survival rate as seen in the following cancers: ovarian (28.3%),
breast (25.2%), colon (13.1%), and lung (4.2%) (Howlader et al., 2014).
Metastasis is a complex, multistep process that involves growth and
vascularization of the primary tumor, invasion and entry into the submucosal
stromal compartment, intravasation into and survival in circulation, avoidance of
immune surveillance, arrest at a distant site, extravasation into the host tissue
bed, and development and proliferation into a clinically detectable metastatic
lesion (>2mm) (Figure 1, Valastyan and Weinberg, 2011).
The most detrimental aspect of metastasis is the general lack of
symptoms until the metastatic tumor is well established and becomes clinically
detectable. At that time, treatment options are limited; therefore, it is therefore
important to understand the underlying mechanisms particularly in the early
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stage of the disease when intervention can have an impact on its progression.
This might also lead to the identification of critical biomarkers that might be used
for early diagnosis or as therapeutic targets to block progression or alleviate
morbidity and mortality from the disease.

1.3 TUMOR MICROENVIRONMENT

AND THE I MMUNE

CELL COMPARTMENT

It is now fully appreciated that a tumor is not simply comprised of a mass
of rapidly proliferating malignant cancer cells (Hanahan and Weinberg, 2011).
Rather, a tumor is comprised of both neoplastic tumor cells and normal nonneoplastic stromal cells that are recruited into and infiltrate the tumor bed. These
supporting stromal cells comprise the tumor microenvironment (TME) and play a
significant role in the growth of all solid tumors.
Host tissue is comprised of two primary cell types, parenchymal and
stromal. Parenchymal cells carry out the primary function of a specific organ; for
example, hepatocytes in the liver and splenocytes in the spleen. Stromal cells,
are located throughout the organ and provide support for the biological function
of the parenchymal cells. In the tumor, stromal cells include blood and lymphatic
endothelial cells, mesenchymal stem cells, cancer-associated fibroblasts,
pericytes, and immune cells, but the stromal composition can vary depending on
tumor location and the origin of the tumor (Sebens and Schafer, 2012). The
stromal cells are recruited to the tumor and support its growth and progression
through the secretion of a diverse collection of cytokines, chemokines, growth
factors, and reactive oxygen species that interact with various signaling pathways
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to activate transcriptional programs that promote uncontrolled proliferation. They
create a permissive tumor microenvironment that is essential to the development
and advancement of many tumors. In a metastatic lesion, parenchymal cells are
infiltrated both by tumor and stromal cells, all of which are involved in signaling
crosstalk which can both promote and inhibit tumor growth. Additionally, many of
these stromal cells, such as the immune cells, can be polarized into either a protumor/immune-suppressive or anti-tumor phenotype and recent clinical evidence
indicates that polarizing normal cells towards their anti-tumor phenotype has
drastic effects on improving survival rates (Suzuki et al., 2016).
The immune cell component of the stroma is highly important to
understanding the tumor microenvironment. In a classic immune response to an
infection with a foreign antigen, T-cells, B-cells, and myeloid lineage cells are
mobilized to clear the infection and then return to an inactivated state (Chaplin,
2010). In the context of cancer, however, immune cells are recruited to a tumor
that they infiltrate where they may exert a pro-tumor phenotype as a
consequence of their plasticity. The primary immune cells found in the tumor
microenvironment include mast cells, myeloid-derived suppressor cells,
macrophages, neutrophils, and T-regulatory cells among other immune cell types
(Hanahan and Weinberg, 2011). Mast cells, the primary cell type responding to
an allergy stimulus, often infiltrate a tumor, correlate with poor prognosis, and
assist in chemotherapeutic drug resistance (Maciel et al., 2015; Oldford and
Marshall, 2015). Myeloid-derived suppressor cells (MDSCs) are immature
myeloid cells found in most tumors which can suppress the T-cell response to the
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growing tumor (Arbab and Achyut, 2016; De Vlaeminck et al., 2016; Moses and
Brandau, 2016). Macrophages and neutrophils arise from the myeloid lineage
and are both highly plastic. Macrophages and neutrophils have a classically
activated M1/N1 anti-infection and anti-tumor phenotype, and an alternatively
activated M2/N2 wound healing and pro-tumor phenotype (Galdiero et al., 2013;
Kim and Bae, 2016). These activated states are extremes on a spectrum of
possible phenotypes, but must be differentiated to study their biological context
accurately. When infiltrating a tumor, macrophages and neutrophils are
designated as “tumor associated” macrophages or neutrophils, TAMs and TANs,
respectively. TAMs and TANs are frequently polarized towards a pro-tumor
phenotype and thus provide a potential target for therapy. In a healthy patient,
these wound healing phenotypes prevent the body from being overwhelmed by
too much inflammation; however, in the context of cancer, immune cell function
can be hijacked into a pro-tumor phenotype that supports the growth of the
tumor.

1.4 THE PRE-METASTATIC NICHE
Metastasis is not a random process (Figure 1.2). As early as 1889 the
British pathologist, Stephen Paget, found that certain primary tumors metastasize
to secondary organs for which they have a specific affinity. Dr. Paget observed in
autopsies of breast cancer patients that metastases developed only in the liver,
bone, and ovaries (Paget, 1989). He postulated that since the spleen receives
much more blood flow than the bone, it should have more metastatic growth,
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however, none of his autopsy patients presented with metastasis in the spleen.
He proposed the “seed and soil hypothesis,” wherein certain “seeds”, i.e., the
primary tumor cells have a preference and will only grow in certain “soil”, i.e., the
secondary organ that provides a permissive environment for the growth of
disseminated tumor cells.
In the 1930’s James Ewing challenged Paget’s hypothesis by suggesting
that metastatic dissemination can be explained solely by hematogenous
circulation (Ewing, 1928). The prevailing theory was that metastasis was
controlled by the pattern of blood and lymph circulation and that capillary beds,
such as those prevalent in the lung, liver, or spleen, were the only targets for
metastatic growth. Prior to this it was thought that tumors only metastasized
purely from the vasculature of organs although some physicians had speculated
such organotropism. Although it has been shown that vasculature has an effect,
the seed and soil hypothesis provides a viable explanation for discrepancies
between blood flow and metastatic growths in an organ (Fidler and Hart, 1982).
In the 1970’s, Isaiah Fidler’s work reignited interest in the seed-and-soil
hypothesis, and in 2005, David Lyden’s group was the first to show that the
formation of a pre-metastatic niche (PMN) in the target organ prior to the arrival
of metastatic cells promoted the establishment and progression of metastasis
(Kaplan et al., 2005). He showed that clusters of immune cells, specifically bone
marrow derived cells (BMDCs) expressing VEGFR1, c-kit, CD133, and CD34,
were recruited to the target organ prior to the arrival of metastatic tumor cells
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where they provided sites for attachment and a favorable environment for the
tumor cells to grow.
The current understanding of the pre-metastatic niche in liver metastasis
is well described in both Azizidoost, et al. and Obenauf and Massagué and is
schematically summarized in Figure 1.3 (Azizidoost et al., 2015; Obenauf and
Massagué, 2015). The liver is the most common site for metastasis of many solid
tumors and is primarily seen in the metastasis of colorectal, pancreatic, and
gallbladder cancers. Liver metastasis is also seen frequently in breast and lung
cancers. The hepatic portal system partially explains colorectal liver metastasis
because the veins of the gastrointestinal tract drain through the capillaries in the
liver, which provides ample endothelial surface area for the tumor cell to
extravasate, arrest, and grow.
Some of the mechanistic details of how the pre-metastatic niche is
developed have begun to unfold over the past decade. Exosomes have been
shown to induce TGF-β production, which activates hepatic stellate (ito) cells and
leads to BMDC recruitment to the liver. IL-6 and CCL2 have also been shown to
induce the recruitment of BMDCs to the liver (Obenauf and Massagué, 2015).
Neutrophils can produce MMP9, which degrades collagen in the basement
membrane of an organ, allowing for an increase in both intravasation and
extravasation of tumor cells. CXCL1, a neutrophil chemoattractant is highly
upregulated in the liver of tumor bearing mice, leading to neutrophil recruitment
(Yamamoto et al., 2008). It has also been shown that neutrophils are capable of
binding to tumor cells leading to their accumulation in the liver (Spicer et al.,

8

2012). By understanding the kinetics and cellular and molecular mechanisms
regulating the organotropism of metastasis and pre-metastatic niche formation, it
may be possible to develop methods to restrict the growth of metastasis in
patients whose tumors have not yet metastasized.

1.5 MOUSE MODELS OF COLORECTAL CANCER METASTASIS
In order to study the cellular and molecular factors effecting metastasis
during colon cancer progression, a clinically relevant and ethically appropriate
model, which can recapitulate the many traits of human metastasis from the
growth of the primary tumor to establishment of metastasis, is essential. Mice
provide an ideal model that has been used by many researchers for cancer
studies. In studies designed to test drugs directly on human tumors, a patientderived xenograph model (PDX) using immune-deficient mice have been very
useful; however to study the biological mechanisms of metastasis and the role of
the tumor microenvironment, a few factors must be controlled. The mice must
have an intact immune system that is able both to respond to pathogens and
infiltrate the tumor and surrounding tissues. Furthermore, the tumor must be
syngeneic to the host strain so that the immune system does not detect the
injected tumor cells as foreign, resulting in their rejection. The tumor must also be
orthotopic, or located in its tissue of origin. As shown in Figure 1.4, a cecal
implantation model for colorectal cancer is ideal for this purpose and can reliably
produce liver metastasis with pre-metastatic niche formation (Zhang et al., 2013).
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In this experimental method, CRC tumor cells that are syngeneic are injected into
the subserosa of the cecum to grow in their native environment.
Additionally a splenic injection model is a useful experimental model that
can be utilized to readily assess the establishment and growth of metastatic cells
upon arrival into the liver (Lim et al., 2015). These mouse models allow for the
kinetics and composition of the hepatic microenvironment to be accurately
studied because they recapitulate many traits of clinically observed tumors in a
rapid, reproducible, and accurate manner. Most importantly for this study, the
immune cells of the mice can be studied, which is vital to precisely understanding
the tumor microenvironment and its interactions with tumor cells. Other mouse
models in use for colorectal cancer studies include cecal and splenic
implantations of human cells into mice lacking some or all cell immune cell types
(Oh et al., 2016).

1.6 LIPOCALIN-2

IN COLORECTAL CANCER AND METASTASIS

Lipocalin-2 (LCN2) is a 25 kD protein that is also known as Neutrophil
Gelatinase Associated Lipocalin (NGAL), oncogene 24p3, or siderocalin. It is a
siderophore binding protein that is primarily associated with the innate immune
response (Goetz et al., 2002). It was initially discovered in the secondary
granules of neutrophils where it was bound to neutrophil gelatinase, also known
as metalloproteinase 9 (MMP9) (Kjeldsen et al., 1993).
In a normal human, the principal role of LCN2 is to bind and sequester the
siderophore enterobactin, primarily secreted by Escherichia coli and Salmonella
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typhimurium, to inhibit bacterial growth by limiting the amount of iron that can be
stolen from the mammalian host to be used in bacterial metabolism. Many
bacterial cells have developed resistance to this mechanism and secrete
siderophores that LCN2 cannot bind (Correnti and Strong, 2012; Neilands, 1995).
During an infection, invading bacteria secrete siderophores to capture iron for
use in cellular processes (Flo et al., 2004). As shown in Figure 1.5, Lipocalin-2
circumvents this hijacking by binding the siderophore and sequestering it back
into a host cell expressing the receptor for Lipocalin-2, Slc22a17 (24p3R) (Bao et
al., 2010; Richardson, 2005).
Not only can Lipocalin-2 bind to the bacterial siderophore, enterobactin,
but it can also bind to the mammalian siderophore, catechol (Correnti and
Strong, 2012; Neilands, 1995). In mammalian cells, LCN2 can both increase or
decrease intracellular iron levels in response to environmental signals (Tandara
and Salamunic, 2012). Upon binding iron, LCN2 binds to the cell surface receptor
24p3R which is then internalized. The iron is released causing intracellular iron
levels to increase. LCN2 can also bind to intracellular iron and shuttle it out of the
cell, reducing iron levels and inducing apoptosis (Bao et al., 2010; Reilly et al.,
2013).
There are multiple studies with contrasting data on the role of Lcn2, which
is likely context dependent; however, there is strong support in the published
literature for a pro-tumorigenic role for Lcn2 in cancer progression. A number of
papers show that elevated levels of Lcn2 correlate with poor prognosis, poor
survival, metastasis, and invasiveness. In multiple studies, colorectal

11

adenocarcinoma patient samples were analyzed by IHC and high NGAL
expression was seen in colorectal cancer specimens, while low or no expression
was seen in adjacent normal tissue (Nielsen et al., 1996) (Lv et al., 2010) (Sun et
al., 2011) (Barresi et al., 2011). Proteomic analysis via mass spectrometry
showed higher LCN2 in colon cancer samples versus normal colon samples
(Conrotto et al., 2008). In rectal cancer patient samples, 69/100 samples showed
LCN2 overexpression which positively correlated with invasiveness, lymph node
metastasis, angiogenesis, and an advanced stage (Zhang et al., 2009). LCN2
was associated with an increase in distant metastasis and advanced cancer
stage in 64 surgically resected colorectal carcinoma tissues (Barresi et al.,
2010). In a study of patients already presenting with hepatic metastasis, serum
LCN2 was significantly higher in patients with three or more metastatic nodes
and in patients with two or more hepatic lobes showing metastases (Martí et al.,
2010). Furthermore, plasma LCN2 was lower in healthy patients as compared to
non-metastatic and metastatic CRC patients (Marti et al., 2013).
Outside of the primary tumor, other studies have begun describing a role
for stromal-derived Lcn2. In McLean et al., LCN2 was expressed in 100% of
adenoma and carcinoma tumor tissues, but only in 4% of tumor adjacent normal
tissue (McLean et al., 2013). This tumor adjacent tissue only expressed LCN2 in
the stromal compartment, but in the tumor tissue, LCN2 was more prevalent in
stroma than in epithelium. In oral squamous cell carcinoma tissue, Shinriki, et al.
showed that LCN2+ neutrophils were significantly associated with lower overall
survival (Shinriki et al., 2014). Recently, it has been shown that Lcn2 from the
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tumor stroma promotes MCF-7 breast cancer metastasis, and is postulated to be
secreted from macrophages in response to tumor cells (Ören et al., 2016).

1.7 GOALS OF THE PROJECT
The overall goal of this project is to understand the changes in the liver
microenvironment prior to and after the establishment of metastases; specifically,
we are interested in the role that the Lipocalin-2 protein plays in this process. We
will test the hypothesis that Lcn2 promotes liver metastasis of colorectal cancer
by altering the hepatic microenvironment by promoting interactions between
tumor cells and cells in the hepatic microenvironment. To understand these
mechanisms, we altered the levels of Lcn2 both in the seed (tumor cells) and in
the soil (hepatocytes and stromal immune cells). We utilized an in-vitro
scratch/migration and matrigel® transwell invasion assays to systematically
delineate Lcn2-specific effects on tumor cell invasion (Corning Incorporated,
2013; Justus et al., 2014). We also utilized a cecal implantation model and
splenic injection model to provide the in-vivo framework to recapitulate the results
we have obtained using the in-vitro methods (Soares et al., 2014; Zhang et al.,
2013). Finally, we analyzed the effects of systemic upregulation of Lipocalin-2,
and its effect on the rate and stromal composition of metastasis. Together, these
studies provide a large volume of data showing the effects of Lcn2 in the liver
metastasis of colorectal cancer.
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Figure 1.1: The metastatic cascade. Metastasis comprises many steps to allow
tumor cells to break into circulation from the primary tumor and travel and arrest to a
distant site to form a metastatic tumor. Reprinted from Cell, Volume 147/Issue 2,
Scott Valastyan and Robert Weinberg, Tumor Metastasis: Molecular Insights and
Evolving Paradigms, Pages 275-292, 2011, with permission from Elsevier.
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Figure 1.2: The seed and soil organotropism of metastasis. As described in
(Valastyan and Weinberg, 2011), primary tumors have organotropism and an affinity
for the supportive environment of certain organs for metastatic growth. Reprinted
from Cell, Volume 147/Issue 2, Scott Valastyan and Robert Weinberg, Tumor
Metastasis: Molecular Insights and Evolving Paradigms, Pages 275-292, 2011, with
permission from Elsevier.

15

Figure 1.3: Model of pre-metastatic niche formation. The primary tumor in the
colon is represented as the “seed” which send out signals systemically. The bone
marrow compartment receives these signals and sends out bone-marrow derived
cells to the liver to pre-condition the liver for the growth of metastatic tumor. The liver
is the “soil” that provides favorable growth to the tumor cells. Upon dissemination
from the primary tumor, CRC cells arrest in the liver at pre-metastatic sites and grow
into clinically detectable metastases. Image: For the National Cancer Institute ©
2011 Terese Winslow LLC, U.S. Govt. has certain rights.
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Figure 1.4: Mouse models of liver metastasis. A) The cecal implantation model. B)
An alternate spleen injection model used to reliably produce liver metastasis via the
spleen.
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Figure 1.5: The known mechanisms of Lipocalin-2 are shown by A) the secretion
of siderophores by invasive bacteria to sequester iron from the host. B) The
presence of bacteria or a tumor induces inflammatory cytokine expression. C)
Lipocalin-2 is expressed and can sequester the siderophore, retaining host iron. D)
Lipocalin-2 can alternatively bind a mammalian siderophore.
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CHAPTER 2
LIPOCALIN-2 IS OVEREXPRESSED IN THE LIVER OF
COLORECTAL CANCER BEARING MICE
2.1 I NTRODUCTION
Despite intensive efforts in cancer research over the past half-century, the
high mortality rates of solid tumors, especially after the establishment of
metastasis, remains a significant problem. In colorectal cancer, survival rates
decrease drastically for patients diagnosed after metastases have grown.
Therefore, it is critical to understand the biological processes occurring during
tumor development prior to and after the establishment of metastasis to develop
therapeutic strategies to lower the high mortality rates in patients presenting with
metastasis.
The complex tumor microenvironment is composed of stromal cells that
are recruited to the tumor in addition to tumor cells that are embedded in the
extracellular matrix in the normal host tissue. It is critical to understand how these
three cellular compartments, tumor, tumor stroma, and non-tumor parenchyma
interact with one another to promote tumor growth and progression.
The overarching goal of this study is to identify genetic changes in the liver
prior to, and after the establishment of metastasis in the liver during colon cancer
progression. This allows us to identify genes whose products may be required to
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prepare the hepatic microenvironment for the arrival of metastatic cells, and
genes whose products are required to sustain metastatic growth and progression
upon arrival into the liver. Using a syngeneic orthotopic cecal implantation model
previously described in Zhang, et. al., we carried out a microarray analysis of
liver tissue in tumor-bearing mice prior to the establishment of metastasis, and
liver tissue after the establishment of CRC metastases. We found that Lipocalin-2
is highly expressed in the liver of metastasis-bearing mice and sought to
determine its role in maintaining metastatic growth. In this chapter, I describe the
microarray analysis and related data, which provides the basis for investigating
the role of Lcn2 in the metastasis of colon cancer (Zhang, 2013).
Cellular signaling between tumor, stromal, and host cells is also of interest
in this chapter as we confirm microarray data by analyzing serum of mice bearing
tumors. The analysis of serum shows the systemic levels of Lcn2 throughout
various stages of metastatic tumor progression.

2.2 RESULTS
2.2.1 MICROARRAY ANALYSES

OF HEPATIC MICROENVIRONMENT DURING

METASTATIC PROGRESSION.

A microarray analysis was performed on tumor bearing mice to determine
genetic changes occurring in the liver during tumor progression (Zhang, 2013). In
the tumor-bearing mice, three groups were established; sham, pre-metastatic,
and metastatic. In addition, microarray analyses were performed to compare the
gene expression signatures of the parental CT26 and the highly metastatic
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derivative CT26-FL3 tumor cells. The following four comparisons were analyzed:
Sham vs. Pre-metastatic, Sham vs. Metastatic, Pre-metastatic vs. Metastatic,
and CT26 vs. CT26-FL3. From this microarray, shown in Figure 2.1, Lcn2 was
the most highly upregulated gene in the metastasis-bearing liver as compared to
the sham group (388-fold higher). Lcn2 was also one of the most highly
upregulated genes in the metastatic-bearing liver versus the pre-metastatic liver
(140 fold higher). Lcn2 was found to be approximately three-fold higher in CT26FL3 as compared to CT26; however, CT26-FL3 produces metastasis at a 10-fold
higher rate as compared to CT26 (Zhang, 2013).

2.2.2 HEPATIC EXPRESSION OF LIPOCALIN-2

INCREASES DURING

METASTATIC PROGRESSION

To confirm the results obtained in the microarray analysis, we quantified
mRNA expression of Lcn2 in liver tissue during tumor progression in mice
bearing tumors from cecal-injected CT26-FL3 cells. Liver mRNA was extracted
from mice at 5, 17, and 30 days after cecal implantation, representing premetastatic and metastatic liver, and analyzed by qRT-PCR. As shown in Figure
2.2, on day 5, Lcn2 expression in liver tissue from mice that had undergone
sham surgery was elevated due to inflammation from the surgery. By days 17
and 30, Lcn2 expression in CT26-FL3-bearing mice was significantly higher than
the sham control group, confirming the results from microarray analysis and
showing that liver expression of Lcn2 increased drastically in metastasis-bearing
livers.
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2.2.3 SERUM LEVELS OF LIPOCALIN-2

ARE ELEVATED DURING

TUMOR AND

METASTATIC PROGRESSION
To confirm the results from mRNA analysis, we analyzed serum protein
levels to better understand how Lcn2 is expressed and localized during tumor
progression. Western blot analysis was performed on mouse sera during tumor
growth and progression to metastasis. As shown in Figure 2.3, Lcn2 protein
levels progressively increased in the serum of tumor bearing mice as compared
to sham injected control mice. The control mice showed an increase in Lcn2 on
day 0 immediately after surgery due to inflammation that was resolved by day 7.
On the other hand, mice bearing tumors from CT26-FL3, exhibited progressively
higher circulating levels of Lcn2 by day 28, as shown in Figure 2.3. Statistical
analysis using the Pearson Correlation Coefficient was performed on the western
blot shown in Figure 2.3A to determine the correlation between the number of
days (weeks) of tumor progression and Lcn2 serum protein levels. The results
(CT26; r=0.6506, r2=0.4233)(CT26-FL3; r=0.7092, r2=0.503) show that there is a
stronger correlation in CT26-FL3 versus CT26 for there to be higher Lcn2 protein
expression during tumor progression. This suggests that factors in CT26-FL3 that
produce higher metastasis are associated with higher Lcn2 in circulation.

2.3 SUMMARY

AND

DISCUSSION

Taken together, these results show that Lcn2 is upregulated in the liver
and in mouse sera during tumor progression, prior to, and after the arrival of
metastatic cells to the liver. Furthermore, the results showed that increased Lcn2
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expression was found in non-tumor cells in the liver during tumor progression;
however, it remains to be shown if this expression was from the hepatocytes or
other stromal cells found in the liver as part of the pre-metastatic or metastatic
niche.
The microarray study validates many of the same genes that have been
shown in previous studies to be upregulated in the pre-metastatic and metastatic
livers of tumor-bearing mice including Egfr, S100a8, S100a9, Saa3, and Cxcl1
(Rafii and Lyden, 2006; Srikrishna, 2011). Many of these genes have been
studied and their mechanistic contributions to metastasis mostly elucidated.
However the role of Lcn2 remains largely unstudied. As the most highly
upregulated gene in the liver of metastatic-bearing mice, Lcn2 is a potentially
high yield protein of interest involved in developing a favorable organ “soil” for the
colorectal tumor cells to metastasize and proliferate. Microarray analysis also
showed CT26-FL3 expressed three-fold higher Lcn2 as compared to CT26;
however this was not likely to be the source of increased Lcn2 in the serum since
the Lcn2 from the non-tumor liver was much more highly upregulated.
The goal of the subsequent chapters is to further delineate these initial
findings of upregulated Lcn2 in the progression of metastasis along the
framework of the “seed and soil” hypothesis. Lcn2 levels in the tumor “seed”
must be investigated. The role of Lcn2 in the hepatic “soil” is of high importance
given the significantly upregulated Lcn2 in the liver during metastasis in our
mouse model. Delineating the immune cell, hepatocyte, and metastatic tumor
cells contribution of Lcn2, and downstream effects of Lcn2 in these

23

compartments must be determined to better understand how Lcn2 affects
metastasis.

Figure 2.1: Microarray analysis of genetic changes in the seed and soil
of colorectal cancer bearing mice . A) Microarray showing relative mRNA in
non-tumor region of liver in mice given sham surgery or CT26-FL3 cecal
implantation in the pre-metastatic and metastatic settings. B) Microarray results of
CT26 and CT26-FL3 fold change in Lcn2 mRNA expression.
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Figure 2.2: Liver “soil” mRNA expression of Lcn2 in tumor bearing mice.
Liver mRNA isolated from sham or tumor-bearing mice analyzed via qRT-PCR for
relative Lcn2 mRNA levels.

Figure 2.3: Circulating levels of Lcn2 in tumor progression. A) Lcn2 levels in
serum increase during tumor progression in CT26 and CT26-FL3 bearing mice as
compared to sham mice. B) Quantification of the western as performed by Image J
analysis.
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CHAPTER 3
THE ROLE OF INTRA-TUMOR EXPRESSION OF LIPOCALIN-2 IN
COLORECTAL CANCER METASTASIS

3.1 I NTRODUCTION
Data from our preliminary in-vivo studies indicate that elevated Lcn2
expression in the liver and Lcn2 protein levels in circulation was correlated with
colorectal cancer metastasis. In this chapter, our goal was to determine if
elevated Lcn2 expression in tumor cells, the “seed”, had an impact on CRC
tumor growth and its metastasis to the liver. We performed in vitro studies to
determine the effect of overexpression or knockdown of Lcn2 expression in CT26
and MC38 colon adenocarcinoma cell lines that were generated in the BALB/C
and C57BL/6 mouse strains. We determined the effects of Lcn2 expression on
tumor growth and invasiveness.
Previous work by Zhang, et al. established CT26-FL3 as a highly
metastatic cell line derived from CT26. CT26-FL3 expresses Lcn2 nearly three
times higher than CT26, but CT26-FL3 gave rise to liver metastasis in 90% of
host mice as compared to CT26, which only gave rise to metastasis in 10%
(Figure 2.1). In addition, the microarray data showed that Lcn2 levels were 300fold higher in liver tissue of mice bearing tumors from CT26-FL3 as compared to

26

sham controls, however, CT26-FL3 only had three fold higher Lcn2 mRNA
expression as compared to CT26 (Figure 2.1). In this chapter we will investigate
if overexpression and knockdown of Lcn2 in CT26, CT26-FL3, or MC38-luc cells
will lead to corresponding increases and decreases in the invasiveness of these
tumor cells.

3.2 RESULTS
3.2.1 EFFECT OF OVEREXPRESSION OF LCN2 IN CT26 AND CT26-FL3
CELLS ON GROWTH AND I NVASIVENESS

To understand the autocrine effects of Lcn2 on primary tumor cells we
measured cellular growth and invasiveness of stably transfected tumor cells.
Figure 3.1 shows mRNA and secreted protein overexpression of Lcn2 in CT26
and CT26-FL3. Figure 3.2 shows that overexpression of Lcn2 did not significantly
impact the growth of either CT26 or CT26-FL3. This data shown also confirms
previous observations by Zhang, et al. which showed that CT26-FL3 grows
slower in-vitro as compared to CT26 cells. To measure the effects of tumor cell
secreted Lcn2 on tumor cell invasiveness, we used an in-vitro trans-well invasion
assay. The results showed that while CT26-FL3 was more invasive than CT26
cells as previously shown by Zhang, et al, overexpression of Lcn2 did not
significantly alter their invasiveness as compared to the vector transfected cells
(Figure 3.2). Thus, Lcn2 did not affect either the growth rate or the ability of cells
to pass through a basement membrane in the transwell assay.
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3.2.2 EFFECT OF LCN2 OVEREXPRESSION ON METASTASIS

OF CT26 AND

CT26-FL3 IN-VIVO.
Although we observe that CT26-FL3 is more invasive than CT26 in-vitro, it
is only by two to three-fold, which does not account for the 9-10 fold higher
metastatic capability of CT26-FL3 in-vivo. To test the effect of Lcn2
overexpression in CT26 and CT26-FL3, 2x105 cells were injected in the spleen of
BALB/C mice and samples were harvested three weeks after the injection. While
cecal implantation allows assessment of spontaneous liver metastasis of
colorectal cancer, splenic injection can provide a measure for the growth of both
poorly and highly metastatic cells upon arrival in the liver, allowing for a
comparison of metastatic colonization by CT26 and CT26-FL3. Furthermore,
stable transfection of CT26-FL3 and subsequent selection with G418, may cause
some loss of its metastatic potency, requiring a number of rounds of selection
through the liver to regain the highly metastatic nature of the cells.
In Figure 3.3, mice bearing splenic tumors of CT26 and CT26-FL3 that
were overexpressing Lcn2 showed no significant differences in primary tumor
growth or metastatic tumor growth. In another experiment using splenic injection,
shown in Figure 3.4, CT26-FL3 overexpressing Lcn2 and CT26-FL3 vector
control were injected in to the spleens of BALB/C and BALB/C Lcn2-/- mice. The
Lcn2 overexpressing cell lines have smaller primary tumor sizes (Figure 3.4.A),
but the total tumor burden was the same, indicating that Lcn2 overexpression
allowed cells to leave the primary tumor and spread more than the vector control
groups. Systemic knockout of Lcn2, also seen in in Figure 3.4, increased liver
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metastasis in both the vector control and Lcn2 overexpression groups.
Interestingly, when spleen and liver masses are added together, there were no
differences, indicating that, in this model total tumor growth was not affected by
overexpression of Lcn2 in tumor cells or by systemic Lcn2 knockout. However,
primary and secondary tumor growths are different, indicating a role for Lcn2 in
metastasis. More specifically, tumor Lcn2 does slightly impact metastasis, but
only when systemic Lcn2 is absent.

3.2.3 EFFECT OF TUMOR CELL OVEREXPRESSION OF LCN2 ON TUMOR
GROWTH AND I NVASIVENESS

OF MC38 CELLS

To verify the results seen with the CT26 and CT26-FL3 cells with Lcn2
overexpression, we utilized the MC38 mouse adenocarcinoma cell line, which is
syngeneic for the C57BL/6 mice. MC38 is less aggressive than CT26 in-vivo, but
metastasis from cecum implantation can be increased to nearly 50% by
passaging through the liver twice as seen with MC38-FL2 (data not shown).
Figure 3.5 shows that Lcn2 mRNA levels were 1000-fold higher in the
MC38-luc Lcn2 overexpressing cell line as compared to MC38-luc cells
transfected with the empty vector. Cellular growth in-vitro was slower in the
presence of Lcn2. Interestingly, Lcn2 overexpressing MC38-luc cells actually
display a phenotype that is less fibroblastic than typical MC38 cells as seen in
Figure 3.5.D. In Figure 3.6, a transwell invasion assay showed that MC38-lucLcn2 cells were two-fold more invasive than Mc38-Luc-Vector cells.
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3.2.4 EFFECT OF LCN2 OVEREXPRESSION ON METASTASIS

OF MC38 IN-

VIVO.

To test the effect of Lcn2 overexpression in MC38-luc cells on metastasis
in-vivo, the cells were injected into the spleens of C57BL/6 mice and allowed to
grow for three weeks. Surprisingly, as shown in Figure 3.7, Lcn2 overexpression
prevented tumor growth in the spleen in-vivo.
To begin to understand the contrasting effects of Lcn2, we measured
secreted levels in both cell lines. The results from ELISA Figure 3.8 showed that
CT26 and MC38-luc cells secreted undetectable levels of Lcn2 protein. On the
other hand, the CT26-Lcn2 cell line secreted 15 pg/mL of Lcn2, while the MC38luc-Lcn2 secreted 7980 pg/mL of Lcn2, approximately 535-fold higher than
CT26-Lcn2. These extremely high levels of Lcn2 are consider hyperphysiological since normal mice can typically have 1000 pg/mL of Lcn2 in serum
while tumor bearing mice have approximately 2000-4000 pg/mL of serum Lcn2.
Lcn2 is a known neutrophil chemoattractant, and it is possible that such high
levels of Lcn2 being secreted from the primary tumor cells might cause
recruitment of anti-tumor immune cells into the spleen to eliminate the tumor cells
(Asimakopoulou et al., 2016a). Collectively, the results showed that in MC38-luc
cells, overexpression of Lcn2 slowed cell growth in-vitro and prevented tumor
growth in-vivo. Additionally, MC38-luc-Lcn2 exhibited altered morphology
towards a less-fibroblastic phenotype as compared to MC38-luc-pGL4.13 and
MC38-luc-Lcn2 suggesting a mesenchymal to epithelial transition.
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An additional data that warrants future studies is the role of iron and Lcn2
in invasion and metastasis. In Figure 3.8.B, MC38-luc-Lcn2 showed no
differences in wound healing as compared to controls. However, when ferric iron
was supplement or iron was chelated with deferoxamine (DFO), MC38-luc-Lcn2
took a significantly longer time to heal the scratch. Since Lcn2 can shuttle iron
into and out of the cell, it is possible that MC38-luc-Lcn2 exports iron with Lcn2
faster than it can uptake iron, so that the lack of intracellular iron could slow
wound healing or migratory activity of cells expressing Lcn2.

3.3 SUMMARY

AND

DISCUSSION

In previous work by Zhang, et al., we observed that orthotopic implantation
of CT26-FL3 produced liver metastasis at a frequency of 90% and under the
same conditions, CT26 produced liver metastasis with 10% frequency (Zhang et
al., 2013). This 9-10 fold increase in invasion in-vivo compared to the 2-3 fold
increase in invasiveness in-vitro indicated that crosstalk with the primary and
secondary tumor microenvironments in-vivo contribute to the high metastasis of
CT26-FL3. This is not surprising since it is well know that the tumor
microenvironment is critical to the growth and development of the primary tumor
and metastatic tumor growth (Hanahan and Weinberg, 2011).
The hyper-elevated Lcn2 protein levels observed in MC38-luc-pGL4.13Lcn2, at around 7000-fold, were hyper-physiological levels that only increased
cell invasion by two-fold (p<0.05) in vitro. However, when injected into C57/B6
mice, MC38-luc-Lcn2 was unable to produce a tumor after 21 days. MC38-luc-
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Lcn2 was also unable to grown in the flank as compared to MC38-luc and only
produced a measurable tumor after three months post-injection (data not shown).
As a known neutrophil chemoattractant, it is probable that such high levels of
Lcn2 from the MC38 primary tumor induced an immune response which
eliminated the tumor from the mouse (Asimakopoulou et al., 2016a).
It is possible that the effects of Lcn2 secreted from the primary tumor on
metastasis are concentration dependent. The data showed that expression of 50fold higher Lcn2 in CT26-Lcn2 and did not increase invasion or metastasis, while
expression of 1000-fold higher Lcn2 in MC38-luc-Lcn2 only led to a two-fold
increase in invasion.
Collectively, these data suggest that Lcn2 does not play a significant role
in tumor growth and progression when over-expressed in tumor cells, the seed
component of the seed and soil hypothesis. This leads to the question on the role
of Lcn2 when expressed in the host parenchymal and stromal compartments.
The current literature suggests that LCN2 expression in human colorectal
cancer is positively correlated with poor outcomes, but this association is
disputed by a number of studies. Candido, et al. found that colon tumors express
LCN2 mRNA approximately 66.3% higher than normal colon tissue, and 45% of
colon tumors express some LCN2 protein, as detected by immunohistochemistry
(IHC) (Candido et al., 2014). Nielsen, et al. showed a positive correlation with
tumor transformation (Nielsen et al., 1996) and Marti, et al, suggested that LCN2
can be utilized in the prognosis of metastatic patients (Marti et al., 2013).
Catalan, et al described LCN2 as a diagnostic marker, however, Fung and
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McLean disagreed that LCN2 can be used as a clinically viable testing option
(Catalán et al., 2011; Fung et al., 2013; McLean et al., 2013). Thus, while it
seems that LCN2 has the potential for clinical utility, its multifaceted role is
unclear and warrants further investigation.
In the subsequent chapters, our goal is to determine if Lcn2 expressed in
the host and stromal cells in the microenvironment plays a role in metastasis as
using both in-vitro and in-vivo strategies. An interesting question to dissect
would be its role in promoting tumor cell invasion or sustaining tumor growth
upon arriving in the secondary environment such as the liver. More recent
studies using human colorectal cancer cell lines suggest that intratumoral LCN2
may inhibit metastasis by polarizing tumor cells into an epithelial phenotype
(Feng et al., 2016) which seem to be consistent with the MC38-luc-Lcn2
phenotype shown in Figure 3.5.D. Future studies would need to investigate the
role that 24p3R, the Lcn2 receptor plays in the primary tumor cells.
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Figure 3.1: Lcn2 overexpression in CT26 and CT26-FL3. A) Plasmids pCMV6Entry and pCMV6-Lcn2. B) CT26 overexpression of Lcn2. C) CT26-FL3
overexpression of Lcn2. D) ELISA showing secreted Lcn2 protein levels confirming
Lcn2 overexpression (Elamparo, 2013).
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Figure 3.2: Lcn2 overexpression does not significantly impact growth or
invasion in CT26 and CT26-FL3. A-C) Growth rates of CT26 and CT26-FL3 cells
overexpressing Lcn2. D-F) Invasion assays showing effects of Lcn2 overexpression
on CT26 and CT26-FL3. G) Representative images of invasion assay results from
3.2.D.
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Figure 3.3: Lcn2 overexpression in CT26 and CT26-FL3 splenic injection. A)
Liver masses of mice bearing Lcn2 overexpressing CT26 and CT26-FL3 tumors. B)
Spleen masses of mice bearing Lcn2 overexpressing CT26 and CT26-FL3 tumors.

Figure 3.4: CT26-FL3 overexpressing Lcn2 in WT and Lcn2-/- BALB/C mice. A)
Lcn2 overexpression in the primary tumor. B) Liver masses of mice bearing Lcn2
overexpressing tumors. C) Total liver and spleen mass from each group.
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Figure 3.5: MC38-luc cells overexpressing Lcn2. A) Plasmid maps of pGL4.14 and
pGL4.14-Lcn2. B) Lcn2 overexpression measured via qRTPCR. C) Western
immunoblot showing intracellular and extracellular Lcn2 overexpression. D) Cellular
phenotype of MC38-luc cell lines. E) Growth assay of MC38-luc clones.

Figure 3.6: MC38-luc cells overexpressing Lcn2 invasion assay. A) Invasion
assay with Lcn2 overexpression MC38-luc cells. B) Representative images of
invasion insert.

37

Figure 3.7: MC38-luc cells overexpressing Lcn2 injected via spleen in C57BL/6
mice. The upper panels show spleens and livers of mice injected with MC38-luc
cells. The lower panels show spleens and livers of mice injected with MC38
overexpression Lcn2 and show no growth in either location.

Figure 3.8: ELISA data of secreted Lcn2 in CT26 and MC38 lines. A) ELISA
shows secreted Lcn2 protein levels (pg/mL) from both CT26 and MC38 cells that are
vector control or overexpressing Lcn2. B) Performing a wound-healing scratch assay,
MC38 control and Lcn2 overexpressing cell lines were scratched under control, high
iron (10 μM FeCl3), and chelated iron (10 μM DFO) conditions.
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CHAPTER 4
THE IN-VITRO ROLE OF TUMOR MICROENVIRONMENT-DERIVED LCN2
IN

TUMOR CELL I NVASION

4.1 INTRODUCTION
The current literature describing the role of Lcn2 in metastasis is
discordant, most likely due to the variety of cancer models used by different labs.
Thus, the burden of proof remains to further delineate the effects of Lcn2 on
colorectal cancer metastasis through experimental methods. Since hepatocytes
comprise the majority of the liver, it is likely that they contribute a significant
portion of the Lcn2 found in pre-metastatic and metastatic livers of colorectal
cancer bearing mice. In a bacterial infection and hepatectomy model, Xu, et al.
showed that hepatocytes secrete ~25% of serum Lcn2 in normal conditions and
~90% of serum Lcn2 levels after infection or injury (Xu et al., 2015).
Macrophages located in the metastatic microenvironment are a likely cell
type that may be influencing Lcn2’s participation in metastasis. Macrophages are
highly plastic immune cells whose gene expression can be modified in response
to cues from the microenvironment allowing them to be polarized into a
continuum of phenotypes. The two oversimplified phenotypes in the macrophage
spectrum are the classically activated pro-inflammatory M1 and the alternatively
activated anti-inflammatory M2 (Mosser and Edwards, 2008). The M2
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designation contains nearly all alternatively activated macrophages and can be
further broken down into the M2a wound healing macrophage and the M2b/c
immune regulatory macrophage. The distinctions between different phenotypes
are often blurred and macrophages can exist in a hybrid state, expressing genes
found in multiple subtypes.
Many papers have shown a role for Lcn2 in the polarization of
macrophages, which can further influence the tumor microenvironment in the
metastatic setting (Guo et al., 2014; Jung et al., 2015). In a bacterial pneumonia
study, LCN2 deactivated macrophages and was a marker of macrophage
deactivation and impaired immune clearance of bacteria (Warszawska et al.,
2013). Jung, et al. showed that IL-10 in the tumor microenvironment caused
downstream production of Lcn2 by tumor associated macrophages that were
polarized towards an M2 phenotype (Jung et al., 2012). In an obesity-associated
inflammation model, Lcn2 was shown to be an anti-inflammatory regulator of
macrophages, skewing towards an M2 phenotype via a feed-forward NF-κBSTAT3 loop (Guo et al., 2014).
In contrast, using an ischemia-reperfusion model, Lcn2 promoted
macrophages towards an M1 phenotype (Cheng et al., 2015). In addition, in a
microglial model, Lcn2 polarized microglia, the resident macrophages of the
central nervous system, into an M1 phenotype (Jang et al., 2013). Jablonski, et
al. showed Lcn2 as one of the most highly upregulated genes (41.8 fold) in M1
vs. undifferentiated M0 undifferentiated macrophages (Jablonski et al., 2015).
However, these classical inflammatory models were very different from tumor-
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bearing models, which all showed Lcn2 expression correlating with the M2
phenotype.
Another hematopoietic cell population that is found in the metastatic
microenvironment is the neutrophil, which has also been shown to promote liver
metastasis (Gordon-Weeks et al., 2017). In healthy humans, neutrophils make up
50-70% of all white blood cells and have been shown to play a role in both antitumor and pro-tumor immunity (Galdiero et al., 2013). Similar to macrophages,
neutrophils can be polarized into a classical N1, anti-tumor phenotype and a protumor, N2 phenotype. Neutrophils found in tumors are designated as tumor
associated neutrophils (TANs), which can be either pro-tumorigenic or antitumorigenic (Sionov et al., 2015).
Neutrophils were the first cell type that was found to express high levels of
Lipocalin-2, hence the name Neutrophil Gelatinase Associated Lipocalin (NGAL).
Gelatinase (MMP9) was found in humans to bind NGAL to prevent the
degradation of MMP9 (Koh and Lee, 2015). Schroll, et al. showed that
recombinant Lcn2 can induce neutrophil migration which is reduced in Lcn2
knockout mice (Schroll et al., 2012).
Our preliminary microarray data showed that Lcn2 is highly upregulated in
the non-tumor area of a murine liver bearing CRC metastasis. The goal of this
chapter is to further understand the role that Lcn2 expressed in the parenchymal
hepatocytes and in hematopoietic immune cells plays in promoting or
establishing liver metastasis of colorectal cancer using in-vitro assays. The
immune cell components that are the primary focus in this chapter are the
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myeloid lineage-derived neutrophils and macrophages. By utilizing a transwell
chamber, we can perform invasion assays by co-culturing the tumor cells with
immune cells. This in-vitro system allows us to simulate metastasis with the
upper chamber representing the primary tumor, or “seed”, and the lower chamber
representing the metastatic site, “or soil.” Altering the levels of Lcn2 in the lower
chamber “soil” cells allows us to develop a framework for the role of Lcn2 from
microenvironmental cell types on colorectal cell invasiveness.

4.2 RESULTS
4.2.1 EFFECT OF HEPATIC LCN2 ON CRC I NVASIVENESS
In this study, we utilized the murine hepatocyte cell line TIB-73 (BNL CL.2
(ATCC® TIB-73™)) to test the role of hepatic Lcn2 expression on CRC cell
invasion. It is a reliable cell line that can be altered via transfection or
transduction. Lcn2 overexpression was established in TIB-73 using the
previously described pCMV6-Entry-Lcn2 plasmid. As shown in Figure 4.1.A,
Lcn2 mRNA was over-expressed, in Figure 4.1.B, intracellular protein levels
decreased for TIB-73 with Lcn2 overexpression, but, most importantly, secreted
Lcn2 protein levels increased, as shown by ELISA in Figure 4.1.C. Consistent
with previous experiments, intracellular Lcn2 protein levels did not always
correspond to mRNA overexpression since Lcn2 is mostly secreted from the
cells. In Figure 4.2, we show that the presence of hepatocytes in the lower well of
a matrigel invasion assay increased the invasiveness of both CT26 and CT26FL3. To determine if increased Lcn2 levels in the “soil”, or the TIB-73 liver cells,
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in the bottom well would have an effect on tumor cell invasion, TIB-73 cells overexpressing Lcn2 were placed in the bottom well during an invasion assay. The
results in Figure 4.2.C showed that increased Lcn2 from the soil (TIB-73
hepatocytes) increased tumor cell invasion.
To determine if increased hepatocyte Lcn2 specifically caused the
increased invasiveness of CT26, Lcn2-specific siRNA was transfected into the
TIB-73 cells as described in the materials and methods chapter. The results in
Figure 4.3 show that siRNA against Lcn2 diminished mRNA levels as determined
by qRT-PCR and extracellular Lcn2 protein levels as determined by ELISA. Lcn2
knockdown via siRNA reduced the invasiveness of CT26, but not to a statistically
significant level. However, a Pearson correlation analysis showed that Lcn2
levels from the TIB-73 cells correlated with invasiveness of CT26 cells to some
extent (r=0.58, r2=0.34).

4.2.2 EFFECT OF LCN2 EXPRESSED BY NEUTROPHILS

ON CRC CELL

I NVASIVENESS.
Another cell type within the metastatic tumor microenvironment that might impact
CRC invasion and metastasis though Lcn2 expression is the neutrophil. The cell
line MPRO (ATCC® CRL-11422™) can be induced to differentiate into mature
neutrophil (NEUT) after four days of exposure to 10 M all-trans-retinoic acid
(ATRA). These differentiated neutrophils (NEUT) express azurophuilic primary
granules, the mouse neutrophil antigen 7/4, and possess chloroacetate esterase
activity seen in primary neutrophils (Gupta et al., 2014; Tsai and Collins, 1993).
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NEUT cells were 72% positive for the cell surface markers Cd11b and Ly6G by
flow cytometry analysis as compared to MPRO cells which were only 12%
positive for both markers. In Figure 4.3.C, qRT-PCR levels indicated that Lcn2
expression increased by approximately 150-fold and the Lcn2 receptor 24p3R
expression increased by approximately 15-fold in NEUT cells as compared to the
undifferentiated MPRO cells. Co-culture of NEUT cells with CT26 cells in
invasion assays showed that the invasiveness of CT26 cells increases nearly two
fold in the presence of NEUT cells as compared to CT26 by itself or with MPRO
cells. Experiments to determine if downregulation of Lcn2 by siRNA transfection
or lentiviral shRNA expression were largely unsuccessful due to the difficulty in
diminishing the very highly elevated Lcn2 mRNA levels in NEUT cells.

4.2.3 EFFECT OF LCN2 IN MACROPHAGES ON CRC CELL I NVASIVENESS
Macrophages are one of the most prevalent immune cell types in the
metastatic microenvironment and our goal was to determine the influence of
Lcn2 in macrophages on colorectal cancer cell invasion (Qian and Pollard, 2010).
Using the Raw 264.7 macrophage-like cell line, we tested some of the effects of
macrophages on cell invasiveness in-vitro. Similar to primary macrophages,
Raw264.7 cells can be polarized into an ‘anti-tumor’ M1 phenotype with LPS or a
‘pro-tumor’ M2 phenotype with IL-4 (Davis et al., 2013). Utilizing the transwell
invasion assay with CT26 or CT26-FL3 in the upper chamber and Raw264.7 cocultured in the bottom well, tumor cell invasion increased dramatically in the
presence of macrophages, as shown in Figure 4.5. Subsequent attempts to
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knockdown Lcn2 via siRNA or shRNA were unsuccessful as Raw264.7 is one of
the most difficult cell types to reliably transfect. To circumvent this difficulty, we
utilized primary bone marrow derived macrophages (BMDMs) from BALB/C mice
or C57BL/6 mice as previously described (Jung et al., 2016; Singh et al.). Bone
marrow was extracted from WT C57BL/6 and C57BL/6 Lcn2-/- mice and
incubated in 15% L-929 conditioned media for 7 days, after which the
F4/80+/Cd11b+ population, corresponding to macrophages, was determined to
be 97.2% by flow cytometry. In Figure 4.5.C, MC38-luc cells were placed in the
top chamber, while the bottom chamber contained either wild type C57BL/6
BMDM or C57BL/6 Lcn2 -/ BMDM. Both wild type and Lcn2-/- BMDM were
treated with either LPS or IL-4 to polarize them into an M1 or M2 phenotype,
respectively. Consistent with the previous results obtained with the Raw264.7
cells in co-culture invasion assays, the presence of BMDMs increased the
invasiveness of MC38-luc cells dramatically (Figure 4.5.C). The loss of Lcn2 from
BMDMs had no impact on the invasion rates for unstimulated or LPS-treated
BMDMs, however, BMDM cell from Lcn2-/- mice, treated with IL-4 showed the
highest levels of MC38-luc invasion. This data suggested that in the M2
phenotype, a factor other than Lcn2 may be contributing to the high levels of
tumor cell invasion.
Figure 4.5.D shows results from ELISA analysis for Lcn2 levels in media
taken from the wells of the invasion assays performed in Figure 4.4.C. Lcn2
levels were highest in B6 BMDM’s treated with LPS (>4,500 µg/mL). The other
wells showed Lcn2 levels of approximately 200 pg/mL, including IL-4 treated
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Lcn2-/- BMDMs, which gave the highest levels of MC38-luc invasion.
Interestingly media from C57BL/6 Lcn2 -/- BMDM’s treated with LPS and
incubated with MC38-Luc cells contained 1000 pg/mL Lcn2, which suggested
that in response to LPS stimulation of BMDMs into an M1 state, the MC38-luc
cells secreted higher levels of Lcn2, however, this has no effect on MC38-luc
invasiveness. The Pearson correlation shown in figure 4.5.E revealed that there
was no association in between Lcn2 levels in the media and MC38-luc tumor cell
invasiveness (r=0.086, r2= 0.007).

4.3 SUMMARY

AND

DISCUSSION

The results shown in these experiments confirmed the data from the
microarray analysis, which suggested that high levels of Lcn2 from cells in the
metastatic microenvironment may be partially responsible for the growth of liver
metastasis of colorectal cancer. Elevated levels of Lcn2 secreted by TIB-73
hepatocytes increased the invasion of CT26 colorectal tumor cells. The
differentiated NEUT neutrophils, which expressed very high levels of Lcn2 also
increased the invasiveness of CT26. On the other hand, while the Raw264.7
macrophages and the BMDMs isolated from wild type or Lcn2-/- mice caused
large increases in tumor cell invasion, loss of Lcn2 in these cells or elevated
levels in the media did not affect tumor cell invasiveness. Collectively, the data
shown here indicated that Lcn2 from specific cells in the tumor microenvironment
and host influenced the invasiveness of CT26, CT26-FL3, and MC38-luc
colorectal tumor cells while Lcn2 from other cells have no effect and may exert
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their effects on tumor growth and invasiveness through other factors. For
example, Raw264.7 cells express less Lcn2 than TIB-73 cells in both their native
states; however, Raw264.7 induced more tumor cell invasion than TIB-73 in the
co-culture invasion assay. This is reasonable as there are a host of cytokines
and chemokines that are involved in the crosstalk between tumor cells and
stromal cells, thus, it is unlikely that any one protein (Lcn2) can be primarily
responsible for singlehandedly driving cellular invasion or tumor phenotype. The
focus of this chapter was to investigate the Lcn2 specific effects on tumor cell
invasion, but it remains possible that in-vivo, Lcn2 may have an effect on the
metastatic cascade in liver metastasis that is not the invasiveness of the
colorectal tumor cells. The subsequent chapter aims to investigate Lcn2 in-vivo in
the hepatic tumor microenvironment.
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Figure 4.1: Lcn2 is overexpressed by transfecting TIB-73 with pCM6-Lcn2. A)
mRNA levels of Lcn2, B) intracellular Lcn2 protein levels as shown by western blot,
and C) extracellular protein levels measured by ELISA confirm Lcn2 overexpression.
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Figure 4.2: Lcn2 overexpression from TIB-73 cells in the “seed” compartment
in a co-culture invasion assay increases invasiveness of CT26 and CT26-FL3.
A) CT26 and B) CT26-FL3 are co-cultured with TIB-73 for an invasion assay. C) Lcn2
overexpression in TIB-73 increases invasion of both CT26 and CT26-FL3.
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Figure 4.3: Lcn2 expression from TIB-73 hepatocytes directly affects
invasiveness of CT26 tumor cells. A) Invasion assay schematic shows the layout
of a co-culture invasion assay with CT26 tumor cells in the upper chamber. To
confirm siRNA knockdown of Lcn2 we observe: B) mRNA levels via qRT-PCR, C)
western blots showing intracellular Lcn2 protein levels, D) quantification of the
intracellular western blots, and E) extracellular protein via ELISA. F) CT26
invasiveness in co-cultured invasion assay is shown for all TIB-73 pVM6-Entry and
TIB-73 pCMV6-Lcn2 clones untransfected or given NC siRNA (non-targeting
control), Lcn2 siRNA 2, or Lcn2 siRNA 3. G) The correlation between Lcn2
extracellular protein in TIB-73 co-culture wells and CT26 invasiveness is shown.
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Figure 4.4: Lcn2 overexpression in neutrophil cell line appears to increase
invasiveness of CT26 tumor cells. A) MPRO cells are induced into NEUT cells
over 4 days and shows normal histology of neutrophils. B) Flow analysis of the
induced neutrophils are 72% positive for Ly6G+/Cd11b+ neutrophil markers. C)
Lcn2 expression and 24p3R expression increases with neutrophil induction. D)
Invasion assay of CT26 co-cultured with un-induced and induced neutrophils shows
that only induced neutrophils increase CT26 invasiveness.
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Figure 4.5: Raw264.7 co-culture increases CT26 and CT26-FL3 invasiveness
but Lcn2 dampens MC38-luc invasiveness shown by a co-culture invasion
assay with Lcn2 knockout BMDMs polarized to an M2 phenotype. A) CT26 and
B) CT26-FL3 invasiveness increases significantly when co-cultured with Raw264.7
during an invasion assay. C) When co-cultured with BMDMs under unstimulated,
M1, and M2 phenotypes, Lcn2 knockout increases MC38-luc invasion under the M2
phenotype only. D) ELISA analysis shows Lcn2 levels in media during invasion
assay corresponding to the groups shown in C. E) Correlation of invasiveness of
MC38-luc with extracellular Lcn2 shows there is no Lcn2-associated trend for
invasion.
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CHAPTER 5
THE ROLE OF LIPOCALIN-2 IN SHAPING THE METASTATIC STROMA OF
COLORECTAL CANCER IN-VIVO
5.1 INTRODUCTION
To better understand the role of Lipocalin-2 in the hepatic tumor
microenvironment in advanced colorectal cancer metastasis, we utilized an
immune-competent mouse model to experimentally recapitulating a
comprehensive tumor microenvironment, which closely represents clinical tumor
physiology. As previously described, we observed increased levels of systemic
Lcn2 and elevated hepatic Lcn2 mRNA levels in our orthotopic cecal implantation
mouse model of colorectal cancer progression and metastasis,. In studies
described in this chapter, we utilized in-vivo electroporation of endotoxin-free
plasmid DNA to increase systemic levels of Lcn2 in tumor-bearing and nontumor-bearing mice. The goal was to determine the effect of increased serum
levels of Lcn2 on the localization of immune cell populations in the metastatic
liver microenvironment.
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5.2 RESULTS
5.2.1 PV1J-LCN2 UTILIZATION

IN MULTIPLE

MOUSE MODELS

Previous work in the laboratory by John Bonaparte showed that mice
electroporated with 50 ug of pV1J-Lcn2 had ~30% higher serum Lcn2 levels than
mice electroporated with pV1J vector only (Bonaparte, 2015, unpublished data).
The higher Lcn2 levels were sustained for 2-3 weeks until gradually dropping
back to pre-electroporation levels. When the electroporation was performed in
mice that have been implanted with MC38-luc cells in the spleen, elevated Lcn2
had no effect on the primary tumor volumes in the spleen. However, elevated
Lcn2 levels resulted in a two-fold increase in liver mass due to increase
metastasis, as compared to mice electroporated with the empty vector
(Bonaparte, 2015). These data suggested that elevated systemic levels of Lcn2
either (1) accelerated the establishment of metastasis or (2) supported the
growth of colorectal cancer tumor cells in the liver after they have disseminated
from the primary tumor. The goal of the experiments in this chapter is to begin to
elucidate the changes in the stromal immune cell populations in the metastatic
liver microenvironment in the presence of high systemic levels of Lcn2 in tumorbearing mice.
To determine if increased CRC metastatic burden from systemic Lcn2
increase is specific to liver metastasis or causes non-specific increases in
metastasis in other cancers, we electroporated pV1J-Lcn2 into a breast cancer
and a melanoma mouse model. These experiments were performed in
collaboration with Lauren Stryzewski as part of her undergraduate Honor’s
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Thesis. In the melanoma model, B16-F10 melanoma cells were injected
subcutaneously into C57BL/6 mice. In the breast cancer model, 4T1-RFP-luc
breast cancer cells were injected into the left 4 th mammary fat pad of BALB/C
mice. In both models, tumor cell implantation was followed by electroporation of
pV1J-LCN2 plasmid or pV1J empty vector. Tumors were allowed to grow for 6
weeks to assess growth and the presence of metastases.
The results in Figure 5.1.A showed the 4T1-luc-RFP tumor
bioluminescence in mice electroporated with pV1J and pV1J-Lcn2. Figure 5.1.B
showed that the primary tumor volume is greater in mice electroporated with
pV1J-Lcn2 during all weeks of tumor progression. Figure 5.1.C showed the
metastatic tumor bioluminescence appears to trend towards being higher in the
pV1J-Lcn2 group, but there is no difference in metastatic burden in these mice. It
is likely that allowing the primary tumors to grow longer may provide more insight
into the effects of high systemic Lcn2 on breast cancer metastasis. Figure 5.1.D
and 5.1.E showed that in C57BL/6 mice injected subcutaneously with B16-F10luc melanoma cells and electroporated with pV1J or pV1J-Lcn2, the pV1J-Lcn2
group showed higher primary tumor mass, but there was no difference in lung
metastasis as shown by IVIS imaging in photons/second.
Taken together, these data showed that elevated systemic Lcn2 levels
enhanced primary tumor growth of both melanoma and breast cancers. In the
splenic model of CRC liver metastasis, which quickly produces liver metastasis
via drainage through the splenic vein, elevated Lcn2 increased liver metastasis
but did not impact primary growth. On the other hand, both breast and melanoma
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primary tumors grew very aggressively and the mice had to be sacrificed due to
the large tumor burden before significant metastasis occurred. Future studies
should utilize a slower growing melanoma and breast cancer mouse cell lines in
conjunction with Lcn2 electroporation, to better gauge the impact of Lcn2 on the
incidence of metastatic growth in other target organs. In conclusion, elevated
systemic Lcn2 levels increased the growth rate of primary breast and melanoma
tumors, and but did not increase incidence of metastasis to lung and liver.

5.2.2 LOCALIZATION

OF L CN2 EXPRESSION IN THE LIVER OF METASTASIS-

BEARING MICE

In the microarray experiment described in Chapter 2, Lcn2 was identified
as a gene of high interest in liver metastasis because it was one of the most
highly upregulated in the liver “soil”. Lcn2 mRNA levels in the microarray was
over-expressed in the non-tumor regions of the liver, as confirmed by the
exclusion of mCherry protein, which was expressed only in the tumor cells.
However, while this analysis showed that Lcn2 is highly expressed in the nontumor region, there was no indication of the specific cell type(s) producing Lcn2.
To identify the cells producing Lcn2 in the liver of colorectal cancer bearing mice,
immunohistochemistry (IHC) and in-situ hybridization (ISH) were utilized.
IHC staining for Lcn2 on metastasis-bearing mouse liver tissue showed
diffuse staining, which is consistent with its role as a secreted protein (Figure
5.2). Lcn2 staining appeared darker on the edges of the tumor region. Although
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myeloperoxidase positive (MPO+) cells, or neutrophils, were found around the
tumor periphery, there was no punctate co-localization of MPO with Lcn2.
In-situ RNA hybridization was used to determine the sites of hepatic Lcn2
transcription. The results in Figure 5.3 showed that Lcn2 is mostly overexpressed around the periphery of the tumor with very few transcripts expressed
within the tumor cells. Figure 5.4 further showed that when adjacent metastatic
liver sections were stained by IHC for the CD45 pan-leukocyte marker (total
immune cells), F4/80+ marker for macrophages, MRP-8 for mast cells, and MPO
for neutrophils, these cellular markers are found in cells within the same region
as the Lcn2 mRNA, however, there was no distinct cellular staining pattern
correlating Lcn2 expression with any one type of immune cells in-situ.

5.2.3 EFFECTS OF INCREASED SYSTEMIC LCN2 ON THE IMMUNE

CELL

COMPOSITION OF THE METASTATIC LIVER MICROENVIRONMENT

After localizing the Lcn2 mRNA expression to the tumor periphery in-situ,
more cell specific Lcn2 co-localization was necessary to determine which stromal
cells were expressing Lcn2. We also wanted to determine how an increase in
systemic Lcn2 levels in tumor-bearing mice affected the metastatic tumor
microenvironment, specifically with respect to the recruitment of macrophages
and neutrophils. CRC patients with high serum levels of Lcn2 had poorer
prognosis and outcomes, thus, it is critical to understand if elevated Lcn2 in
CRC-bearing mice was contributing to CRC metastasis or if it is a downstream
byproduct of the high inflammation seen in tumor bearing mice.
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We used a splenic injection model in these experiments by injecting
MC38-luc CRC cells directly into the spleen. The high vascular drainage from the
spleen into the liver allows metastasis to occur in all animals injected. MC38-luc
is a very useful tumor model because it is less aggressive than CT26 and
provided a more fine-tuned window in which to observe changes due to high
systemic Lcn2 expression. In-vivo electroporation of pV1J-Lcn2 was used to
elevate systemic Lcn2 in tumor-bearing mice given a splenic implantation of
MC38-luc. Lcn2 and immune cell co-localization were analyzed using
fluorescence confocal microscopy. Analysis by flow cytometry was used to
further quantitate the cell populations identified by confocal microscopy including
leukocytes (Cd45+), macrophages (F4/80+), neutrophils/MDSCs
(Cd11b+/Ly6G+), and mast cells (Cd117+/FcεR1α+). Figures 5.8-5.11 show that
electroporation of Lcn2 caused minimal to no change in immune cell populations
in non-tumor bearing mice, therefore, only the results obtained from tumorbearing mice are described below. Figure 5.7 shows the fold change in immune
cell populations in the spleen, liver, and liver metastases of tumor-bearing mice
electroporated with either pV1J or pV1J-Lcn2.

TOTAL IMMUNE CELLS
As shown in Figure 5.5.D, analysis by confocal microscopy showed no
differences in the CD45+ cell population between pV1J and pV1J-Lcn2
electroporated mice. Flow cytometry analysis of the CD45+ population showed
that, as expected, tumor bearing mice electroporated with pV1J or pV1J-Lcn2
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had more spleen and liver immune cells than non-tumor bearing mice, due to the
role of immune cells in supporting the tumor microenvironment. Figure 5.8.B
shows two populations in pV1J-Lcn2 tumor bearing mice at sacrifice because the
two mice being analyzed varied in tumor burden.

MACROPHAGES
The results in Figure 5.5.C showed that in the pV1J-Lcn2 electroporated
mice, a significantly higher number of macrophages infiltrated the tumors at the
tumor-liver periphery, as compared to mice electroporated with the pV1J vector.
Analysis of resected tumors by flow cytometry analysis for the F4/80+ cell
populations are shown in Figure 5.9. Tumor-bearing mice showed a significant
decrease in spleen F4/80+ cells, but an increase in liver F4/80+ cells. In these
tumor-bearing mice, only pV1J-Lcn2 electroporated mice showed a 1.7-fold
increase in the number of macrophages in the liver as compared to vector
electroporated mice. In addition, metastatic liver tumors in mice electroporated
with pV1J-Lcn2 were infiltrated with 1.75-fold more macrophages than those
electroporated with the pV1J vector.

NEUTROPHILS
Analysis of tumor bearing liver sections by confocal microscopy showed
that there were no differences in MPO+ neutrophil populations within the tumors
of mice electroporated with pV1J (Figure 5.5,C). Quantification of the MPO+
populations showed no changes in their numbers at the tumor periphery when
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systemic Lcn2 level was increased by electroporation with pV1J-LCN2 (Figure
5.6). In contrast, we observed a change in the number of Cd11b+/Ly6G+
neutrophil/G-MDSC population between the spleen and liver (Figure 5.10). Flow
cytometry analysis of single cell suspensions from spleen and liver taken from
tumor bearing mice four weeks after electroporation showed that mice with
elevated Lcn2 had fewer neutrophils in the spleen and a higher number of
neutrophils in the liver (Figure 5.10). These changes in population suggest that
neutrophils may be recruited into the metastasis bearing liver in response to
Lcn2, but not into the metastatic tumor bed.

MAST CELLS
A similar analysis of tumor bearing liver sections by confocal microscopy to
examine the number of Mct+ mast cells and flow analysis of single cell
suspensions from spleen and liver for Cd117+/FceR1a+ mast cells showed no
significant differences in their numbers in mice electroporated with pV1J or pV1JLcn2 (Figure 5.11). Notably, the flow analysis showed fewer mast cells infiltrating
liver metastatic tumors in mice electroporated with pV1J-Lcn2 as compared to
pV1J; however, their numbers were so low such that their role in the tumor
microenvironment in relation to Lcn2 overexpression may not be significant.

QUANTITATION

OF CELL POPULATIONS BY CONFOCAL MICROSCOPY.

In Figure 5.6.A, we quantitated the Lcn2+ cells in metastasis bearing liver
and found that there were higher numbers of Lcn2+ neutrophils in mice
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electroporated with pV1J. When Lcn2 systemic levels were elevated by
electroporating with pV1J-LCN2, the population shifted such that there was a
higher number of Lcn2+ macrophages in the liver. Overall examination of Lcn2+
cells however, indicated that most of these cells were neither neutrophils nor
macrophages (Figure 5.6.B). Although there is no reliable cellular marker for
mouse hepatocytes, the histology and morphology of the Lcn2+ cells in the tissue
sections indicate that these are mostly hepatocyte cells. Although we observe a
change from more neutrophils expressing Lcn2 to more macrophages expressing
Lcn2 in response to pV1J-Lcn2 electroporation, most of the macrophages within
the tissue sections did not express Lcn2, ( Figure 5.5). These observations
suggest that in all tumor-bearing mice, Lcn2 is predominantly produced by
hepatocytes around the periphery of the metastatic lesion, and when systemic
Lcn2 is elevated, infiltration of metastatic tumors by macrophages increases to
potentially sustain metastatic proliferation.
To assess the effects of macrophages infiltration of metastatic tumors
under high Lcn2 conditions, we subcutaneously injected MC38 CRC cells
admixed with BMDMs in to C57BL/6 mice. As shown in Figure 5.12, addition of
undifferentiated BMDMs had no impact on tumor burden. However, addition of
BMDMs conditioned with IL-4 that polarized the macrophages to the M2
phenotype caused a dramatic increase in tumor burden. Furthermore, loss of
Lcn2 in macrophages conditioned to the M2 phenotype, by using Lcn2-/- BMDMs
isolated from Lcn2-/- mice, reduced the magnitude of tumor growth seen in WT
M2 BMDMs, but this reduction was non-significant due to the high variance.
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Follow up experiments repeating this M2 BMDM co-injection with MC38 in the
splenic injection model may show the impact of macrophage infiltration in
proliferation of metastatic lesion in the presence of elevated Lcn2.

5.3 SUMMARY

AND

FUTURE DIRECTIONS

The data show that elevated systemic Lcn2 in a tumor-bearing mouse
increased tumor burden in colon, breast, and melanoma cancers in mice, but
increased primary tumor growth only in breast and melanoma models and
increased metastatic burden in the MC38 spleen injection model. This suggests
that high systemic Lcn2 increases tumor burden in mice, but whether it manifests
in increased metastasis depends on the kinetics of the specific tumor model. The
flow cytometry data suggest that under conditions of high systemic Lcn2
expression, total immune cell and mast cell populations do not change; however,
a percentage of macrophages and neutrophils decreases in the spleen and
increase in the liver, but only macrophages invaded the tumor margins under
high systemic Lcn2 conditions. Confocal microscopy showed that in mice
electroporated with pV1J-Lcn2, there is an increase in the number of
macrophages infiltrating the metastatic tumor margins in the liver. These
macrophages correlated with increased metastasis, however, more work needs
to be done to show that macrophages directly promote metastatic growth.
Our data further showed that hepatocytes are the predominant Lcn2producing cells in the metastatic liver microenvironment. This is supported by the
observations that 1) Lcn2 mRNA transcripts were localized around the periphery
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of metastatic tumors in-situ, 2) intracellular Lcn2 protein was colocalized with
hepatocyte cells in confocal microscopy analyses, and 3) minimal Lcn2 protein
colocalized with non-hepatocyte cells in confocal images.
The data suggests that elevated systemic Lcn2 may increase
inflammation, which may cause increased infiltration of macrophages into the
metastatic tumors. Lcn2 in the hepatocytes around the edges of the tumor may
support tumor growth through this recruitment. Lcn2 may also support tumor
growth by acting as an alternative iron-transport mechanism by increasing the
iron available to metastatic tumor cells (Gomez-Chou et al., 2017; Jung et al.,
2017).
Lcn2 has been described as a downstream product of the IL-6/STAT-3
axis in hepatocytes and macrophages, and IL-1β as a positive regulator of Lcn2
production via NF-κB (Asimakopoulou et al., 2016b; Feng et al., 2016; Gineste et
al., 2016; Guo et al., 2014; Kienzl-Wagner et al., 2015; Moschen et al., 2017;
Warszawska et al., 2013; Xu et al., 2015). Since IL-6 is a well-established
cytokine upregulated in many tumors, including CT26 and MC38, tumor-derived
IL-6 may contribute to downstream Lcn2 expression in hepatocytes, among
many other proteins driven by IL-6/STAT-3 signaling (Miller et al., 2016)(Li et al.,
2012).
Other studies have investigated the role of iron and Lcn2 in macrophages
and the data suggest that M1-polarized macrophages tend to store iron in ferritin
and M2-polarized macrophages store iron in a labile iron pool, wherein iron is
more accessible to chelation by Lcn2 and a siderophore (Corna et al., 2010). A
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recent study showed that macrophages with an ‘iron-releasing’ phenotype in the
tumor microenvironment aid in tumor progression (Mertens et al., 2016). Future
studies utilizing these BMDMs and CRC cell lines could investigate the role that
Lcn2 and STAT3 play in conjunction with macrophages and iron.
Future directions for this study should look to differentiate between the
effects of Lcn2 on metastasis when Lcn2 is synthesized only in hepatocytes or
immune cells. Utilizing a hepatocyte specific Lcn2 knockout model, we could
determine if systemic Lcn2 causes hepatocytes to secrete Lcn2, or if hepatocyte
Lcn2 caused macrophage infiltration of the tumor margins (Xu et al., 2015). Bone
marrow transplantation of Lcn2-/- BM into WT mice and vise-versa would further
reveal the effects of knocking out Lcn2 specifically in immune cells. To further
investigate the role of macrophages in these processes, clodronate liposomes
could be used in tumor-bearing mice to eliminate all macrophages. Finally, Lcn2
can be transported into cells via the Lcn2 receptor 24p3R. 24p3R-/- mice are
embryonic lethal, but if a drug or antibody were able to inhibit this this receptor, it
would reveal the extent of Lcn2 transport between hepatocytes and immune cells
and if that affected liver metastasis of CRC.
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Figure 5.1: Electroporation of pV1J-Lcn2 increases primary tumor burden in
breast cancer and melanoma cell lines. A) IVIS imaging shows bioluminescence of
primary and secondary tumors in pV1J and pV1J-Lcn2 electroporated mice given fat
pad injection of 4T1-luc-RFP. B) Primary tumor volume and C) metastatic tumor
bioluminescence are shown. D) Primary tumor mass for C57BL/6 mice bearing B16F10-luc cells. E) Bioluminescence in the lungs of mice bearing B16-F10 melanoma.
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Figure 5.2: IHC staining of liver metastasis tissue for Lcn2 and Mpo. Lcn2
protein localization is diffuse throughout liver tissue of tumor bearing mouse. Lcn2
and MPO IHC staining is shown, but no co-localization is observed.
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Figure 5.3: Liver metastasis tissue stained by H&E and in-situ RNA
hybridization of Lcn2 mRNA. Lcn2 mRNA is expressed in cells at the tumor
periphery around the tumor margins.
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Figure 5.4: In-situ RNA stain for Lcn2 compared to IHC stained for immune
cells in liver metastasis tissue. The liver tissue is surrounded by tumor tissue and
Lcn2 mRNA is detected in the same region as CD45, F4/80, MRP-8, and MPO.

Figure 5.5: Confocal microscopy adjacent sections from liver metastasis of
MC38-luc bearing mice electroporated with pV1J or pV1J-Lcn2 showing liver
(L) and tumor metastasis (M) regions and MPO+, F4/80+, MCT+, and CD45+ cell
populations. pV1J-Lcn2 group shows increased macrophage infiltration into
metastatic tumor.
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Figure 5.6: Quantification of confocal results at metastatic tumor-liver
periphery from pV1J and pV1J-Lcn2 electroporated MC38-luc bearing mice. A)
Immune cells that are positive for Lcn2 quantified. B) Total Lcn2+ cells differentiating
between neutrophils/macrophages and hepatocytes. C) Fold change of immune cells.
D) Fold changes in macrophage cell population at tumor liver periphery in control and
tumor-bearing mice electroporated with pV1J or pV1J-Lcn2.

Figure 5.7: Quantification of flow cytometry results shows fold change of pV1JLcn2 over pV1J electroporation in cell populations of the spleen, liver, and liver
metastasis compartments of tumor-bearing mice only.
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Figure 5.8: Flow analysis of Cd45+ immune cells. Mice given a sham or MC38-luc
splenic injection were electroporated with pV1J or pV1J-Lcn2 and the Cd45+ cell
populations were quantified in the (A) spleen, (B) liver, and (C) primary or metastatic
tumors.
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Figure 5.9: Flow analysis of F4/80+ macrophages. Mice given a sham or MC38-luc
splenic injection were electroporated with pV1J or pV1J-Lcn2 and the F4/80+ cell
populations were quantified in the (A) spleen, (B) liver, and (C) primary or metastatic
tumors.
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Figure 5.10: Flow analysis of Cd11b+/Ly-6G+ neutrophils and G-MDSCs. Mice
given a sham or MC38-luc splenic injection were electroporated with pV1J or pV1JLcn2 and the Cd11b+/Ly-6G+ cell populations were quantified in the (A) spleen, (B)
liver, and (C) primary or metastatic tumors.
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Figure 5.11: Flow analysis of Cd117+/FcεR1α+ mast cells. Mice given a sham or
MC38-luc splenic injection were electroporated with pV1J or pV1J-Lcn2 and the
Cd117+/FcεR1α+ cell populations were quantified in the (A) spleen, (B) liver, and (C)
primary or metastatic tumors.
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Figure 5.12: Co-injection of M2 BMDMs with MC38 increases subcutaneous
tumor burden. Mice were given a subcutaneous injection of 2x105 MC38 cells with
5x104 BMDMs from WT or Lcn2-/- mice and BMDMs were either unstimulated or
stimulated with IL-4 to polarize to the M2 phenotype.
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CHAPTER 6
MATERIALS AND METHODS

Mouse Strains
BALB/C mice were used as orthotopic homograft recipients for the
syngeneic CT26 and CT26-FL3 adenocarcinoma cell lines. C57BL/6 mice were
used at the orthotopic homograph recipient for MC38-luc adenocarcinoma cell
lines. Lipocalin-2 knockout mice in the C57/BL6 background were obtained from
Tak Mak (Princess Margaret Cancer Center, University Health Network, Toronto,
ON). These mice were backcrossed to the BALB/C background over 10
generations. A commercial Lipocalin-2 knockout mouse strain (B6.129P2Lcn2tm1Aade/AkiJ) was obtained from Jackson Laboratories (Bar Harbor, ME).
All BALB/C, C57BL/6, and B6.129P2-Lcn2tm1Aade/AkiJ mice were purchased
from Jackson Laboratories and were bred and maintained at the Mouse
Experimentation Core Facility of the Center for Colon Cancer Research at the
University of South Carolina in Columbia, SC. All animal experiments were
conducted according to the guidelines and approval of USC Institutional Animal
Care and Use Committee.
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Cell culture
The cell lines CT26 (ATCC® CRL-2638™), MPRO (ATCC® CRL11422™), B16-F10 (ATCC® CRL-6475™), and 4T1 (ATCC® CRL2539™) were
purchased from American Type Culture Collection (ATCC®). The cell lines
Raw264.7 (ATCC® Tib-71™), BNL CL.2 (ATCC® Tib-73™), and MC38-luc cells
were kindly given as a gift from Dan Dixon. The highly-metastatic CT26-FL3 was
isolated from the parental CT26 cell line by in vivo selection by injecting into the
cecum and passaging three times through the liver as described (Zhang et al.,
2013). Cell lines CT26, MC38-luc, BNL CL.2, B16-F10, and Raw264.7 were
grown in DMEM (4.5 g/L glucose, 110 mg sodium pyruvate/L and Lglutamine)(Mediatech, Inc. Corning, Manassas, VA) with 10% FBS and 1%
Penicillin-Streptomycin (HyClone, Thermo Scientific, Logan, UT). Cell line 4T1
was grown in RPMI-1640 (Mediatech, Inc. Corning, Manassas, VA) with 10%
FBS and 1% Penicillin-Streptomycin. Dissociation of adherent cells was
performed with Trypsin EDTA 1x (Mediatech, Inc. Corning, Manassas, VA) after
washing cells in Hanks’ Balanced Salt Solution (HBSS) (Mediatech, Inc. Corning,
Manassas, VA). MPRO cells were grown in DMEM supplemented with 10% FBS,
1% Penicillin-Streptomycin, 10 ng/mL Recombinant Mouse GM-CSF (Biolegend,
San Diego, CA). Induction of MPRO into a differentiated neutrophil (NEUT) was
performed by adding 10μM all-trans-retinoic acid (ATRA, Acros Organics, Morris
Plains, NJ) over a minimum of 3 days. Differentiation into NEUT was confirmed
with wright-giemsa staining and flow cytometry. 4T1 cells (ATCC® CRL-2539™)
were grown in RPMI-1640 (Corning, Manassas, VA). All cells were transfected
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using Lipofectamine 2000 (Invitrogen, Waltham, MA). MC38-luc was transfected
with pGL4.14-Lcn2-Hygro and selected with 400 g/mL Hygromycin (Hygrogold,
Invivogen, San Diego, CA). CT26 and CT26-FL3 were transfected with pCMV6Lcn2 (Origene, Rockville, MD) and selected with 400 g/mL G418 Sulfate
(Mediatech, Inc. Corning, Manassas, VA).

Cecal Implantation of Colon Cancer Cells
Surgical laparotomy was performed for cecal implantation of sygeneic
colon tumor cells on mice that were 8 to 12 weeks of age. Cell lines were
dispersed into a single cell suspension and washed twice with PBS immediately
before implantation. Mice were anesthetized with 2% isoflurane in oxygen by
inhalation using a nose cone. Mice were placed in a supine position, and covered
with a surgical drape. A midline saggital incision was created and the cecum was
exteriorized. 2 x 106 tumor cells in a volume of 10-20 L were injected into the
cecal subserosa, sealed with VetBond™ tissue adhesive (3M™, St. Paul, MN)
and sterilized with 70% ethanol to remove any tumor cells that may have leaked
out. The cecum was replaced into the peritoneal cavity and the skin was sutured
in two layers with 6-0 polyglycolic acid absorbable sutures (CP Medical, Portland,
OR). The peritoneum was sutured with a continuous subcuticular pattern, and the
epithelium sutured with a simple cutaneous interrupted pattern. Sham mice were
given the surgical laparotomy with PBS injected into the cecal subserosa.
Postoperative care for the mice included an intraperitoneal (IP) bolus injection of
0.5 cc PBS and 0.1 cc Buprenorphine (0.03%) to manage post-operative pain.
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Splenic Implantation of Colon Cancer Cells
Surgical laparotomy was performed for splenic implantation of sygeneic
colon tumor cells on mice that were 8 to 12 weeks of age. CT26 cells were
implanted into BALB/C mice and MC38 cells were implanted into C57BL/6 mice.
Cell lines were trypsinized into a single cell suspension and washed twice with
PBS before implantation. Mice were anesthetized with 2% isoflurane in oxygen
by inhalation using a nose cone. Mice were placed in a supine position, and
covered with a surgical drape. A dorsoventral incision was made in the left upper
quadrant of the abdomen and the spleen was exteriorized. 2 x 105 tumor cells in
a volume of 10-20 L were injected into the spleen, sealed with VetBond™ tissue
adhesive (3M™, St. Paul, MN) and sterilized with 70% ethanol to remove any
tumor cells that may have leaked out. The spleen was inserted back into the
peritoneal cavity and the skin was sutured in two layers with 6-0 polyglycolic acid
absorbable sutures (CP Medical, Portland, OR). The peritoneum was sutured
with a continuous subcuticular pattern, and the epithelium sutured with a simple
cutaneous interrupted pattern. Sham mice were given the identical surgical
procedure with PBS injection into the spleen. Postoperative care for the mice
included an intraperitoneal (IP) bolus injection of 0.5 cc PBS and 0.1 cc
Buprenorphine (0.03%) to manage post-operative pain.

Mammary Fat-Pad Implantation of Breast Cancer Cells
A subcutaneous injection into the fourth mammary fat pad was performed
on BALB/C mice using sygeneic 4T1 breast cancer tumor cells on mice that were
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8 to 12 weeks of age. Cell lines were trypsinized into a single cell suspension
and washed twice with PBS before implantation. Mice were anesthetized with 2%
isoflurane in oxygen by inhalation using a nose cone. Mice were placed in a
supine position. 5 x 103 tumor cells in a volume of 50 L were injected into the
fat pad. Sham mice were given the identical surgical procedure with PBS
injection into the spleen. Postoperative care for the mice included an
intraperitoneal (IP) bolus injection of 0.5 cc PBS and 0.1 cc Buprenorphine
(0.03%) to manage post-operative pain.

Subcutaneous Implantation of Tumor Cells
Subcutaneous implantation of tumor cells was performed using CT26 cells
in BALB/C mice, MC38 cells in C57BL/6 mice, and B16-F10 melanoma cells in
C57/bl6 mice. Tumor cells were placed in single cell suspension and washed
with PBS twice. 1 x 106 cells were injected with a 31G in 50 μL under the
cutaneous layer of the mouse in the lumbar region on the dorsal surface of the
mouse. The injection site was sealed with a drop of VetBond™ tissue adhesive
(3M™, St. Paul, MN).

Transwell Migration and Invasion Assay
The invasion assay measures tumor cell capacity for breaking through a
matrigel™-coated transwell insert (BD Biosciences, San Jose, CA). 1x105 cells
were starved 24 hours in 0.1% FBS in DMEM and seeded in the top chamber in
0.1% FBS in DMEM. The lower chamber contained 10% FBS in DMEM and the
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cells were allowed to migrate for 20 hours. The matrigel to DMEM dilution was
1:6 (1.43 mg/mL) for CT26 and 1:10 (0.91 mg/mL) for MC38 cells. Co-culture
transwell assays were completed as described above with 1x105 cells of interest
seeded on the bottom well to nearly 75% confluency prior to the start of the
assay. To harvest the assay, cells were fixed in 4% paraformaldehyde and
stained in 1% crystal violet. Cells were imaged and counted in five field views at
40x for each transwell chamber.
Migration assays were performed in 6-well plates, growing cells to 75%
confluence. At the start of the assay, media was switched to 2% FBS in DMEM
and each well was scratched three times using a p200 pipette tip. Cells were
imaged every 24 hours at 40x using the EVOS imager until the wound was
recovered with cell growth or 120 hours. Iron supplementation with 10 μM ferric
chloride (Sigma, St. Louis, MO) and iron chelation with 10 μM deferoxamine
(Sigma, St. Louis, MO) were added to the media of cells after initial scratch was
performed for MC38-luc cells.

Cell proliferation assay
To determine the growth rate of MC38-luc, CT26, CT26-FL3, and their
Lcn2 overexpressing lines in culture, 10,000 cells per well containing 2 ml of
DMEM with 10% FBS were plated into 6-well plates. CT26, CT26-FL3, and their
Lcn2 overexpressing lines were plated at 1x105 cells per well in 6 well dishes in
triplicate and counted at 72 hours, 144 hours, 192 hours, and 240 hours. MC38-
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luc and MC38-luc-Lcn2 lines were plated at 5x105 cells per well in 6 well dishes
in triplicate and counted at 40 hours, 90 hours, and 145 hours.

RNA Isolation
Total RNA was isolated either from cells or murine tissues using the
RNeasy RNA isolation kit (Qiagen, Valencia, CA) or E.Z.N.A.® Total RNA Kit I
(Omega BioTek, Norcross, GA) . cDNA was synthesized from the total RNA
extract using iScript cDNA synthesis Kit (Bio-Rad, Hercules, CA). The kits were
used following manufacturer’s instructions.

Microarray Analyses
Liver samples for microarray analyses were obtained from three groups of
mice. The first group mice, called the sham surgery control underwent the
surgery for cecal implantation but PBS was injected into cecum instead of tumor
cells. The pre-metastatic liver samples were taken from mice with cecal tumors
but no liver metastases. The metastatic liver samples were taken from tumor
bearing mice with liver metastases. Tumor cells were labeled with red
fluorescence. Care was taken that the liver samples were free of tumor tissues
by verifying that the samples did not contain red fluorescent proteins by confocal
microscopy and by ensuring that RNA samples did not contain transcripts from
red fluorescent protein by RT-PCR. In addition, liver samples were confirmed to
be free of tumor cells by analyzing DNA extracted from the tissue for mCherry
sequence via PCR amplification. The RNA samples for microarray analysis were
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isolated, prepared, and analyzed as described in Zhang et.al (Zhang, 2013).
RNA purity was determined by measuring an RNA Integrity Number (RIN) of at
least 8.

Analysis by Quantitative Real-Time PCR
Quantitative Real-Time PCR (qRTPCR) was performed on cDNA samples
using an Applied Biosystems 7300 Real Time PCR System (Thermo Fisher
Scientific Inc., Waltham, MA) with PowerSYBR® green reagent (Life
Technologies, Carlsbad, CA). qRTPCR Primers against mouse transcripts for βactin and Lcn2 were designed and obtained from Integrated DNA Technologies
(IDT, Coralville, IA). The primer sequences are as follows:
β-actin-F, 5’-AAGAGCTATGAGCTGCCTGA–3’,
β-actin-R, 5’–TACGGATGTCAACGTCACAC–3’;
Lcn2-F, 5’–CTACAATGTCACCTCCATCCTG–3’,
Lcn2-R, 5’-ACCTGTGCATATTTCCCAGAG–3’.
Measurements were run in triplicate and transcription levels were determined
relative to β-actin expression levels.

Serum Isolation
Blood serum was collected in Heparin-coated capillary tubes or EDTAcoated vials (Thermofisher, Pittsburg, PA; Becton Dickinson, Franklin Lakes, NJ)
via retro-orbital puncture from mice anesthetized with 2% isoflurane in oxygen.
Samples were centrifuged at 13,700 rcf for four minutes using the ADAMS Micro-
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Hematocrit II centrifuge (Becton Dickinson, Franklin Lakes, NJ) to separate the
serum from red blood cells. Sera were stored in microcentrifuge tubes at -80ºC
prior to analysis.

Western Blotting
Protein extracts were obtained from whole cell lysates or murine blood
sera. Isolation of protein in-vitro was performed using M-PER (mammalian
protein extraction reagent, Thermofisher, Grand Island, NY) with a protease
inhibitor (Sigma, St. Louis, MO) following manufacturer’s instructions. Proteins
were separated on 4-15% precast acrylamide gels (Bio-Rad, Hercules, CA),
transferred to nitrocellulose blots, and probed with primary with antibodies
against Lcn2 (1:500 to 1:1000, Goat pAb and Rat mAb, R&D Systems,
Minneapolis, MN or Rabbit pAb, Abcam, Cambridge, MA). Blots were incubated
with primary antibodies overnight at 4ºC, washed with PBS/0.01% Tween-20,
probed with HRP-conjugated secondary antibody (Bio-rad, Hercules, CA) for 1
hour at room temperature, washed, and visualized with ECL enhanced
chemiluminescence kit (GE Healthcare, Piscataway, NJ). Blots were visualized
using either the GE ImageQuant LAS 4000 (GE Healthcare Bio-Sciences,
Pittsburgh, PA) or the Konica Minolta SRX-101A tabletop radiograph machine
(Konica Minolta Medical Imaging, Wayne, NJ). As internal controls for equal
loading, blots were re-probed with either Hrp-conjugated Anti-β-actin (Abcam,
Cambridge, MA) or Anti-Albumin Rabbit pAb (Santa Cruz Biotechnology, Santa
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Cruz, CA) after stripping the blot with a mild stripping buffer. Western images
were quantified using ImageJ software (NIH, Bethesda, MA).
Enzyme-Linked Immunosorbent Assay
ELISA was performed on serum and cell culture supernatant using the
Mouse Lipocalin-2/NGAL Quantikine ELISA Kit (R&D Systems, Minneapolis,
MN). Serum was diluted 100-fold before analysis. Cell culture supernatant was
diluted if needed to produce a result in the working range of the assay. ELISA
wells were read using the Epoch microplate spectrophotometer (Biotek,
Winooski, VT). Absorbance was read at 450 nm, and optical imperfections in the
plate were read at 540 nm and subtracted from the 450 nm read. Four parameter
logistic ELISA curve fitting analysis was performed on ELISAanalysis.com.

Plasmid Construction and Overexpression of Lipocalin-2 in pCMV6 vector
The pCMV6-Entry plasmid expressing murine Lcn2 was purchased from
Origene and transfected in CT26 and CT26-FL3 cells. A pCMV6-Entry vector
control plasmid was created by excising the Lcn2 sequence from the plasmid and
subsequently transfecting into the CT26 and CT26-FL3 cells as well. The cells
were analyzed for intracellular and extracellular protein levels using western
blotting and ELISA; relative mRNA levels were measured via qRT-PCR.

Plasmid Construction and Overexpression of Lipocalin-2 in pGL4.14 vector
The Lcn2 gene was excised from the pCMV6-Entry-Lcn2 plasmid with
EcoRI and SmaI (New England Biosciences, Ipswich, MA). The Lcn2 fragment
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was ligated into pBluescript KS(-). Subsequent digestion was performed with
HindIII and XbaI to insert Lcn2 into pGL4.13-hygro to make pGL4.14-Lcn2. To
construct the vector control pGL4.14-Lcn2 was digested with BglII and BamHI to
produce pGL4.14. MC38 cells obtained were already transfected with a plasmid
expressing luciferase that was G418 resistant. The pGL4.14-Lcn2 or the
pGL4.14 empty vector was stably transfected into MC38-Luc cells by selection in
Hygromycin.

Histology
Tumor-bearing mice were sacrificed and the liver, spleen, and cecum
were excised and fixed in freshly prepared 4% paraformaldehyde in PBS, pH 7.2.
Tissue blocks were embedded in paraffin, 5 μm sections obtained and then
stained with hematoxylin and eosin (H&E) (VWR, West Chester, PA) for visual
examination.

Immunohistochemistry and RNA in-situ hybridization
The paraformaldehyde-fixed, paraffin-embedded tissue sections were
deparaffinized, rehydrated, and incubated in a microwave oven with 0.01M citrate
buffer, pH 6.0 for 10 minutes for antigen retrieval. Nonspecific epitopes were
blocked with IgG-free bovine serum albumin (Jackson ImmunoResearch, West
Grove, PA) for 1 hour. The sections were incubated overnight at 4ºC with
antibodies against Lcn2 (R&D) at 1:200 dilution). This was followed by incubation
with the corresponding secondary antibody conjugated to horseradish peroxidase
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(HRP) (Bio-Rad, Hercules, CA) for 1 hour at room temperature (RT). Antigen
signals were detected using the 2-Solution Diaminobenzidine (DAB) Kit
(Invitrogen, Frederick, MD), counterstained with hematoxylin, mounted in
Acrymount (StatLab, Mckinney, TX), and visualized under a light microscope.
For RNA-ISH, slides were prepared as described for
immunohistochemistry and then the using the mouse Lcn2 RNAscope ® kit from
ACD (Advanced Cell Diagnostics, Newark, CA) and slides were visualized under
a light microscope.

Confocal microscopy
The liver was excised from mice given a splenic injection and
electroporated with pV1J or pV1J-Lcn2 at 29 days when mice present with
advanced metastatic disease. The samples were fixed in freshly prepared 4%
paraformaldehyde in PBS, pH 7.2. Following fixation, the tissues were rinsed with
PBS and vibratome sections were cut at 100 μm thickness. Adjacent sections
were cut and stained for H&E and samples were selected to view tumors and
liver tissue in the same sample. Samples were stained with primary antibodies:
Lcn2 (Rab Pab, Boster Biological Technology, Pleasanton, CA), MPO, F4/80,
Mast cell tryptase. Secondary antibodies AF488 anti-rabbit, AF647 anti-goat, and
Dylight405 anti-rat (Jackson ImmunoResearch, West Grove, PA) were used.
Nuclei were stained with 1:10,000 dilution of 4’,6-diamidino-2-phenylindole
(DAPI) (Invitrogen, Carlsbad, CA) or Propodium Iodide at a dilution of 1:1000.
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Samples were imaged on a Zeiss LSM510 META confocal scanning laser
microscope.

Bioluminescent Imaging of mice
Mice were imaged for bioluminescence of luciferase-expressing tumor
cells using the IVIS Lumina instrument (Perkin Elmer, Waltham, MA). Mice were
placed under 2% isoflurane inhalation anesthesia via nose cone both in the
preparatory chamber and in the IVIS imaging chamber. Mice were given an i.p.
injection of 150 mg/kg of XenoLight D-Luciferin (Perkin Elmer) and imaged at
least 10 minutes post-injection. Imaging was captured using Living Image
software (Perkin Elmer) and adjusting the exposure time to fall within the
saturation limits of the acquisition camera. Regions of interest were cordoned off
and the bioluminescent counts were converted to photons/second for analysis of
tumors in the mice.

siRNA Knockckdown of Lcn2
Lcn2 knockdown was achieved using the TriFECTa® RNAi kit from IDT
(Integrated DNA Technologies, Coralville, IA) comprised of Dicer-substrate short
interfering RNAs (DsiRNAs). Primers consisting of 3 Lcn2 specific DsiRNAs, 1
TYE563 transfection control, and 1 negative control (NC). siRNA primers were
transfected using Lipofectamine ® RNAiMAX transfection reagent (ThermoFisher,
Pittsburg, PA). TIB-73 and MPRO were given 10 mM siRNA in 6 well plates three
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times before harvesting conditioned media, intracellular protein, and mRNA to
analyze Lcn2 transcription and translation levels.

Electroporation
BALB/C or C57BL/6 mice that were 8 to 12 weeks of age depending on
the application, were used. The lower abdominal quadrant and adjacent leg were
shaved. Mice were anesthetized with 2% isoflurane in oxygen by inhalation using
a nose cone and placed in a supine position. A longitudinal incision is made with
scissors on the ventral surface of the hind limb between the knee and hip of a
mouse. 50 G of plasmid DNA is injected with a 30G needle in a total volume of
50 uL (1ug/uL) into the quadriceps muscles of the mice. Electrodes are placed
both sides of the leg muscles and electroporated for 8 pulses at 100 mV for 50
ms. Electroporated mice have serum isolated and ELISA was performed to
determine that Lcn2 is upregulated in the blood circulation.

Harvesting and Culturing BMDMs
Bone marrow derived macrophages were isolated from C57BL/6 or
B6.129P2-Lcn2tm1Aade/AkiJ Lcn2 knockout mice by flushing femur and tibia
bone marrow into RPMI under sterile conditions. Bone marrow was plated on
uncoated petri dishes and allowed to grow for 8 days under RPMI with 15% L929
conditioned media. Media with macrophage colony stimulating factor (M-CSF)
was prepared by growing L929 (ATCC ® CCL-1™ ) mouse fibroblast cells in
175mm flask for 1 week and harvesting all conditioned media. After 8 days,
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BMDMs were analyzed via flow cytometry for Cd11b+ and F4/80+ population to
be over 95%. These BMDMs can be cultured and used for up to 21 days after
isolation from the mice.

Statistical Analysis
All data are shown as the mean ± standard deviation (SD); comparisons of
two groups were analyzed using the two-tailed t-test with Welch’s correction
using GraphPad Prism version 5.00 for Windows, (GraphPad Software, San
Diego California USA, www.graphpad.com). P-values of p<0.05, p<0.01, and
p<0.001 are indicated with (*), (**), and (***), respectively, and all considered
statistically significant.
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